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INTRODUCTION 
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Introduction 
 
In cirrhotic patients there is an increased susceptibility to bacterial infection, related to the 
degree of liver dysfunction (1-7) leading to several abnormalities of defense mechanisms, all 
of which increase the susceptibility to infection, including deficiency of bactericidal and 
opsonic activities (8;9), impaired monocyte function (10), depressed phagocytic activity of the 
reticuloendothelial system (RES) (11;12), defective chemotaxis (13), and low levels of 
complement in serum (14). 
A particularly important role is played by the reduced RES activity, which is due to the 
presence of extrahepatic shunts and intrahepatic shunts through sinusoids without Kupffer 
cells, a reduced number of Kupffer cells, and impaired Kupffer cell function (15). Thus  
cirrhotics with impaired RES phagocytic activity (as assessed by the elimination of 99m 
technetium-sulfur colloid) develop acute bacterial infections more frequently than cirrhotics 
with normal RES phagocytic activity (12). 
 
Both community (4) and hospital acquired (16) bacterial infections are frequently diagnosed 
in cirrhotics (17), the most frequent being spontaneous bacterial peritonitis (SBP), urinary 
tract infections, pneumonia and skin infections (4), their incidence increasing with the 
severity of liver dysfunction (4;18-20). Importantly, half of these episodes may be 
asymptomatic (3). 
Recently bacterial infections and/or endotoxaemia have been associated with failure to control 
variceal bleeding (21), more early variceal rebleeding (22), abnormalities in coagulation 
(23;24), vasodilatation of the systemic vasculature (25) and worsening of liver function (26). 
There is an increased recognition that bacterial infections are involved in several 
pathophysiological abnormalities in cirrhosis, so that in this introduction we aim to evaluate 
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the potential mechanisms and the clinical evidence illustrating the pivotal role of bacterial 
infection. This could lead to new treatment strategies. 
 
 
Endotoxaemia in cirrhosis 
 
Endotoxaemia in liver disease was first described in 1970 in patients with biliary obstruction 
(27) and it is frequently found in cirrhotics (28-34), even in the absence of any signs of sepsis 
(28). Thus there are higher endotoxin concentrations in peripheral blood of cirrhotics than in 
normal subjects (32;33) with a statistically significant gradient between portal and peripheral 
blood (33), highlighting the role of the bowel as the source of endotoxin. Both peripheral and 
portal levels of endotoxaemia are correlated with the severity of liver disease (29;32;33;35) 
which is more important than porto-systemic shunting or portal hypertension as a major factor 
associated with of plasma endotoxin concentration (28;32). 
 
 
Bacterial overgrowth, altered intestinal motility and increased intestinal permeability 
 
Alteration of small bowel motility, bacterial overgrowth in the small intestine, and increased 
intestinal permeability are all factors leading to increased endotoxaemia, the incidence of 
bacterial translocation and ultimately the risk of bacterial infection in cirrhotics.  
In cirrhotic rats with ascites, bacterial overgrowth results from intestinal hypomotility, and 
bacterial translocation only occurs in presence of overgrowth and severe disruption of the gut 
barrier (36). 
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In humans with cirrhosis, bacterial overgrowth has been shown in one third of alcoholic 
cirrhotics, especially those with ascites and severe liver dysfunction (37), and is associated 
with reduced small bowel motility (38), hypochlorhydria (39), decrease in intraluminal 
immunoglobulins and reduced secretion of IgA (40). In addition, an abnormal colonization of 
the small bowel by colonic bacteria has been found in cirrhosis (41). The alteration of small 
bowel motility is due to a prolonged intestinal transit time (42) which is related to portal 
hypertension by stimulation of neurons through changes in the intestinal wall (43). The 
altered small bowel motility in cirrhosis worsens with severity of liver disease (44;45). A 
coordinated motor function of the bowel is probably the most important mechanism for 
preventing bacterial overgrowth (36). 
 
Intestinal permeability is impaired by portal hypertension (46), particularly in patients who 
are Child grade C (47) or have an alcoholic aetiology (48), especially when there is ongoing 
alcohol intake (49). Mucosal abnormalities of the gastrointestinal tract (leading to increased 
permeability) secondary to portal hypertension, are also found in cirrhotic patients (40). 
Overproduction of nitric oxide (NO) is constantly present when there is portal hypertension, 
leading to disruption of the integrity of the intestinal epithelium (50). In one study, intestinal 
permeability was assessed in 80 cirrhotic patients (mostly alcoholic): an increase in 
permeability was found to be correlated to the occurrence of septic complications (47). 
 
SBP is a haematogeneous infection localising in the ascitic fluid with the source of the 
infecting bacteria most likely being the gut through bacterial translocation. A history of SBP 
is associated with more severe intestinal dismotility and more frequent bacterial overgrowth 
(38;40). Bacterial overgrowth leads to bacterial translocation (51) and together with increased 
intestinal permeability leads to an increased risk of SBP and also worsening of hepatic 
encephalopathy (52-55). 
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Cisapride and antibiotics (such as norfloxacin and neomycin) improve both small intestine 
dysmotility and bacterial overgrowth in cirrhosis (56). Interestingly, propranolol, which 
lowers portal pressure, reduced the risk of post surgical infections in a cohort of 73 cirrhotic 
patients (15 % vs 42 %) (57). The mechanism may not only be by lowering portal pressure 
but also by increasing motility of the bowel by its sympatholytic action, thus indirectly 
decreasing microbial translocation to the systemic circulation. A recent retrospective study of 
139 patients suggested that propranolol may prevent SBP (58). Thus propranolol could have 
another mode of action in reducing variceal rebleeding by preventing or reducing bacterial 
translocation, thus reducing the frequency of infection which may be a trigger for bleeding 
(59). 
 
 
Bacterial translocation 
 
The term bacterial translocation was first coined by Berg and Garlington (60), and was later 
defined as the passage of both viable and non-viable microbes and microbial products, such as 
endotoxin, from the intestinal lumen through the epithelial mucosa into the mesenteric lymph 
nodes (MLNs) and possibly other organs (50). 
 
There are multiple routes by which an organism potentially could translocate from the gut to 
extra-intestinal sites (retrograde migration to the lungs, direct transmural migration across the 
intestinal wall, lymphatic migration via Peyer’s patches, MLNs, the thoracic duct and the 
systemic circulation or via vascular channels to reach the portal system) (50), but in the 
setting of liver cirrhosis the intestinal macrophages seem to play a key role by carrying 
bacteria from the gut to MLNs (61). 
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The principal factors that normally prevent bacterial translocation are the balance of intestinal 
bacterial populations (essentially controlled by peristalsis), the integrity of the intestinal 
barrier and immunocompetence (17). 
 
In addition decreased killing of bacteria may be responsible for increases in colony-forming 
units in the MLNs, rather than an increase in transepithelial penetration (50), as most 
microbes which breach the epithelial barrier are killed (62). Thus, for bacterial translocation 
to become clinically significant, a failure of local and/or systemic immune defence, as is 
commonly present in cirrhotic patients, is also required (50). 
 
In experimental models of liver cirrhosis, bacterial translocation has been reported to occur 
with an incidence ranging from 37 to 83 % (50). Portal hypertension is one factor determining 
bacterial translocation, as it increases in cirrhotic rats after the development of ascites (63), 
but other factors also have a role, such as reduced defenses and bacterial overgrowth (64). A 
lower rate of translocation has been observed in portal vein ligated rats with chronic 
prehepatic portal hypertension but without parenchymal liver damage, which also have milder 
histological changes in the bowel (64;65). In human cirrhosis, the incidence of bacterial 
translocation is also related to the degree of portal hypertension and liver dysfunction, and is 
found in approximately 30 – 40 % of cirrhotics with ascites (36;63;66;67) and is more 
frequent in Child C compared to Child A and B cirrhosis (66). 
 
Only a few types of intestinal bacteria are able to translocate into mesenteric lymph nodes: 
Escherichia coli, Klebsiella pneumoniae, other Enterobacteriaceae, Pseudomonas aeruginosa, 
Enterococci and some Streptococci (68). These bacteria constitute up to three quarters of 
microorganisms isolated in SBP (69). In cirrhotic rats, genotype identity is frequent between 
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the ileal flora and the bacteria colonizing mesenteric lymph nodes (70). A recent study found 
that 7 of 17 advanced cirrhotic patients with culture-negative, nonneutrocytic ascites had the 
simultaneous presence of bacterial DNA in blood and ascitic fluid at admission to hospital 
and which persisted in blood for 24-72 hours (71). Furthermore, nucleotide sequencing 
demonstrated that bacteria detected in the first sample were identical to those noted in 
subsequent detections over time, proving that bacterial translocation is a single-species, 
dynamic process (71). Cirrhotics are also predisposed to spontaneous infections other than in 
ascites (72-76) by intestinal bacteria (72;75-77) as a consequence of bacterial translocation 
(63). Selective intestinal decontamination with antibiotics reduces bacterial translocation (66) 
and decreases the risk of infections, especially those due to Gram negative bacteria (78;79). 
This again supports the role of intestinal bacteria as a source for infections in cirrhotics and 
may explain why prophylactic antibiotics both orally and intravenously are so effective in 
reducing infections during variceal bleeding (80). 
 
 
Effects of endotoxaemia and infection 
 
Chronic exposure to sublethal levels of endotoxin may prime liver parenchymal cells for 
production of NO when exposed to increased levels of endotoxin and/or TNF-α (81). NO 
itself may prime monocytes to endotoxin (82), as well as other biological mediators, released 
by endothelial cells when exposed to biomechanical stimuli such as shear stress in portal 
hypertension. In ascitic cirrhotics, monocytes are spontaneously activated mainly by enteric 
bacterial products to produce TNF-α and contribute in a major way to the elevated serum 
TNF-α (83). In response to endotoxin, in cirrhosis, there is an increased release of TNF-α, IL-
1 and IL-6 and an increased expression of CD11b/CD18 on the surface of monocytes (82;84), 
not only due to the preactivation status of monomacrophages but also due to a reduced 
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catabolism of cytokines accompanying hepatic dysfunction (85-87). Cirrhotic patients with 
bacterial infection have very large concentrations of endotoxin in the systemic circulation and 
a marked and sustained increase in TNF-α and IL-6 concentrations (88). These remain high 
for a longer time as compared to non infected decompensated cirrhotics and non cirrhotic 
infected patients (88). Treatment with norfloxacin in a recent study in 60 alcoholic ascitic 
cirrhotic patients normalised the increased number of monocytes, reduced their activated 
phenotype and their ability to produce TNF-α (83). 
 
As endotoxin is primarily removed by Kupffer cells (89), the hepatic RES modulates most of 
the effects of endotoxin on the liver (such as increase of ICAM-1 expression on hepatocytes, 
endothelial cells and macrophages) (90). Clinically, the increased endotoxin concentrations 
may lead to increased disturbance of the systemic and regional circulations, coagulopathy, 
encephalopathy, and lead to both renal and hepatic failure and ultimately death, in chronic as 
well as acute liver disease (28;34;91-95). 
 
 
Influence of infection on haemodynamics 
 
Arterial vasodilation, particularly in the splanchnic circulation, is a major causative factor in 
the pathogenesis of the hyperdynamic circulatory syndrome that is well documented in 
cirrhosis with portal hypertension (96). The impairment in vascular contractility with 
hyporeactivity to vasoconstrictors in cirrhosis (97;98) is due to overproduction of NO 
(97;99;100), the major source being endothelial nitric oxide synthase (NOS) (101), as well as 
other mechanisms (102). 
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Bacterial translocation, in the presence of portosystemic shunting and reduced hepatic 
clearance, leads to the presence of bacteria, endotoxins and cytokines in the systemic 
circulation (25;50), thus enhancing NO production (103-105). The latter occurs via a direct 
stimulatory effect of endotoxin, but also by endotoxin induced secretion of cytokines such as 
TNF-α and via GTP-cyclohydrolase I which increases tetrahydrobiopterin (BH4) synthesis (an 
essential cofactor in synthesis of NO) (106). This increase in NO further aggravates arterial 
vasodilation in cirrhosis (17;25;107). 
 
Cirrhotics with bacterial translocation have haemodynamic derangement (108). Systemic 
vacular resistance (SVR) is lower and cardiac output higher in cirrhotic patients with 
endotoxaemia than in those without (32); Moreau et al observed that cirrhotic patients with 
septic shock had lower vascular resistances than patients with septic shock without cirrhosis 
(109). Levels of lipopolysaccharide binding protein (LBP), a surrogate marker of 
endotoxaemia, are increased in 40 % of cirrhotics with ascites, but not in cirrhotics without 
ascites (108), suggesting that the increase in nitrate levels due to endotoxaemia and bacterial 
translocation might be related to worsening of portal hypertension and/or liver function. This 
is in agreement with the finding that serum nitrate levels not only correlate significantly with 
endotoxaemia (29) but are also increased in cirrhotic patients with ascites or kidney failure 
and are associated with high plasma renin activity, aldosterone and anti-diuretic hormone 
levels and low urinary sodium in cirrhotics (29).  Very interestingly, selective intestinal 
decontamination can normalize LBP levels, reduce renin and nitrate levels and increase SVR 
in these patients, but it had no effect on patients with normal LBP (108). In another study, 
cirrhotic patients with high TNF-α concentrations in mesenteric lymph nodes (suggesting 
bacterial translocation) had a higher cardiac index and a higher portal pressure (110). In rats 
with portal hypertension, inhibition of TNF-α production is accompanied by amelioration of 
the hyperdynamic syndrome and even a decrease in portal pressure (111-113). These studies 
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suggest that endotoxaemia and bacterial infection can exacerbate the haemodynamic 
alterations in cirrhosis, thus leading to a further worsening of portal hypertension via 
activation of neurohumoral pathways and further fluid retention in response to systemic 
vasodilatation. The correlation between the presence of endotoxaemia or bacterial 
translocation and the worsening of the haemodynamic status is confirmed by the fact that 
intestinal decontamination reduces nitrate and endotoxin levels and vasodilation, both in 
cirrhotic patients (29) and in an experimental rat cirrhotic model (114). In the latter study 
intestinal decontamination also reduced the development of ascites (114). In a human study 
basal forearm blood flow and the vasoconstrictive effect of the NOS inhibitor, NG-
monomethyl-L-arginine was increased in cirrhotics compared to controls but returned to 
normal in cirrhotics after selective intestinal decontamination with norfloxacin (115). In a 
recent study in 14 patients with alcoholic cirrhosis (25), selective intestinal decontamination 
reduced serum endotoxin concentrations and partially reversed the chronic peripheral and 
systemic vasodilatation by increasing SVR and mean arterial pressure and decreasing cardiac 
output and forearm blood flow. Interestingly, HVPG was also decreased by a mean of 2.43 
mm Hg (25), further strengthening the hypothesis that bacterial products contribute to the 
hyperdynamic circulation and portal hypertension in cirrhosis. 
 
In addition to the direct effects of the release of vasoactive mediators such as NO with regard 
to the worsening of the haemodynamic derangement in infected cirrhotics, the release of 
inflammatory mediators may also play a role. Tumour necrosis factor alpha (TNF-α) is 
involved in the pathogenesis of the hyperdynamic syndrome in portal hypertension (111;112); 
the gut and its associated lymphoid tissue produce and release TNF-α in response to bacterial 
translocation even in the absence of portal or systemic spread of bacteria (116;117). Vascular 
reactivity in cirrhotic rats with bacterial translocation to the MLNs is more impaired than in 
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those without translocation and is most likely due to an increase in endothelial NOS activity 
mediated by TNF-α (103).  
 
Renal failure in SBP occurs in the setting of an intense inflammatory response and is related 
to deterioration of circulatory dysfunction (as shown by higher aldosterone and 
norepinephrine levels and plasma renin activity) (118); it can be viewed as the result of the 
combined circulatory dysfunction of cirrhosis, and sepsis, thus leading to additional 
stimulation of the renin-angiotensin system. Cirrhotics with SBP who developed renal 
impairment had significantly higher ascitic fluid levels of neutrophils and both plasma and 
ascitic fluid levels of TNF-α and IL-6, than those without renal impairment (119). 
Hepatorenal syndrome (HRS), which is accompanied by the most extreme haemodynamic 
derangement in cirrhosis, is associated with increased concentrations of IL-6 and TNF-α, as 
compared to patients with liver failure and normal renal function (120). After liver 
transplantation, IL-6 and TNF-α levels return to near normal, concomitant with improving 
renal function, suggesting that IL-6 and TNF-α emanating from the liver may play a role in 
HRS (120). This could be either through TNF-α induced oxygen radical formation by 
mesangial cells (121) or through TNF-α related increase in NO by mesangial (122) or 
endothelial cells (123). Another link between inflammation and haemodynamic dysfunction is 
the finding that  patients with gross ascites had increased levels of C-reactive protein (35) and 
that serum nitrate levels were correlated to levels of orosomucoid (a protein synthesized by 
the liver in response to cytokines) (124;125). Treatment with intravenous albumin in addition 
to antibiotics reduces the likelihood of renal impairment in SBP (126), not only by albumin 
expanding the decreased plasma volume but possibly also by binding of cytokines or NO 
(127-129) or its antioxidant effect in sepsis (128;130;131). Renal failure occurs frequently in 
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patients with variceal bleeding so that bacterial infection may contribute directly to this over 
and above any hypotension which can lead to acute tubular necrosis. 
 
Endotoxin also stimulates the synthesis of endothelin (132), the renal production of 
thromboxane A2 (133) and increases the plasma levels of leukotrienes (134), all of which act 
as renal vasoconstrictors. This release of vasodilators and renal vasoconstrictors due to 
infection may be another factor contributing to the development of renal impairment in SBP 
(135). 
 
The most consistent clinical data on the influence of bacterial infection on systemic 
haemodynamics in cirrhotic patients has been reported in the setting of SBP: renal impairment 
develops in one third of patients (135), especially in those with the highest degree of 
inflammation as expressed by higher concentrations of cytokines in plasma and ascites 
(118;119). SBP is associated with a worsening of the haemodynamic status as shown by the 
activation of the renin-angiotensin system (119) caused by the decrease in effective arterial 
blood volume as a result of infection (119;135). Treatment with cefotaxime and albumin as 
compared to cefotaxime alone leads to less renal impairment and lower mortality, and lower 
levels of plasma renin activity (126). Thus in SBP circulatory dysfunction develops which 
may be prevented by albumin treatment. Recently, in another study (118) WHVP and HVPG 
increased (from 19.0±2.6 to 23.6±2.6 mm Hg, p<0.025) in 8 cirrhotic patients with SBP and 
renal failure despite a decrease in effective arterial blood volume and the systemic 
vasodilatation. This emphasizes the differential effect that the same stimulus can have on the 
systemic and splanchnic circulations. When SBP is associated with systemic circulatory 
dysfunction there is an increase in HVPG, which is thought to be secondary to the action of 
endogenous vasoconstrictors on vascular smooth muscle cells in small venules and on 
activated hepatic stellate cells (myofibroblasts) (136). In the setting of portal hypertension 
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there is a relative deficiency in NO in the intrahepatic circulation, thus increasing the 
susceptibility to vasoconstriction (15).  
 
Endothelin-1 (ET-1) is the most potent mediator of stellate cell contraction (137) and in the 
liver ET-1 receptors predominate in hepatic stellate cells (138), which have an important role 
in the regulation of intrahepatic portal hypertension in cirrhosis (139). Both endotoxin itself 
and the cytokines released in response to it, are potent stimuli for the production of ET-1 (59), 
which may act in combination with cyclooxygenase products to increase portal venous 
resistance during endotoxaemia (140). In the cirrhotic liver there is a greater induction of the 
vasoconstrictor (ET-1) over vasodilatory forces (NO, carbon monoxide) after 
lipopolysaccharide (LPS) injection (141). There is a compromised ability to upregulate 
sufficient vasodilatory forces to counterbalance the constrictive effect of ET-1 following 
increases in endotoxaemia, thus leading to increased intrahepatic resistance. This would result 
in an acute increase in portal pressure. 
 
Other vasoconstrictors such as angiotensin II and norepinephrine can also lead to an increase 
in intrahepatic resistance in rats and in vitro models (136;142;143) and thus lead to an 
increase in portal pressure (118). These mediators are increased in cirrhosis and are further 
augmented in response to the systemic vasodilatation occurring in bacterial infection. 
 
Thus, if infection has a causal role in precipitating variceal bleeding then it could be acting via 
an increase in portal and/or variceal pressure secondary to a rise in intrahepatic resistance as 
we have previously outlined as part of our hypothesis suggesting infection may be a trigger 
for variceal bleeding (21). 
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Influence of infection on coagulation 
 
Using thromboelastography (TEG), 20 cirrhotic patients who had bled from varices, and then 
suffered early rebleeding were found to have a worse TEG trace on the day before rebleeding 
as compared to those who did not rebleed (144). TEG parameters have also been found to 
worsen in 84 decompensated cirrhotic patients in the presence of bacterial infection (145). A 
recent study found heparin activity in blood by using heparinase I-modified TEG in 28 of 30 
patients with bacterial infection, but not in non-infected patients, and this effect disappeared 
after resolution of infection; other coagulation parameters were not modified significantly 
(23). This heparin activity was subsequently found to be associated with anti-Xa 
concentrations in many, although not all patients, suggesting that the heparinase effect is due 
to an endogenous low molecular weight heparin (24). 
 
In a single study plasma heparan sulphate concentrations were significantly raised in patients 
with recent variceal bleeding as compared to those without bleeding or non cirrhotic patients 
(146). Endotoxin or cytokines could release heparinoids from endothelium in a dose-
dependent manner (23) and mast cell activation due to bacterial infection could also release 
heparin. Mast cells and activated endothelial cells also are able to release tissue plasminogen 
activator (t-PA), which induces fibrinolysis (23).  
 
Sepsis causes defects in platelet aggregation (147), and this may constitute another reason for 
an impairment of the haemostatic process in cirrhotic patients, either via a decrease in platelet 
aggregation due to NO (148) or due to the fact that endotoxin and ET-1 can impair platelet 
aggregation through the release of prostacyclin (149-151). 
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The production of cytokines in the presence of bacterial infection can lead to the activation of 
clotting factors and fibrinolysis (152;153). In 30 % of patients with advanced liver disease an 
accelerated intravascular coagulation and fibrinolysis has been shown, and these patients are 
prone to develop DIC if sepsis occurs (154).  
Hyperfibrinolysis has been directly associated with gastrointestinal haemorrhage in cirrhotic 
patients (155-158); unfortunately presence of infection was not documented in these studies. 
Bleeding from oesophageal varices has some correlation with the circadian rhythm of 
fibrinolysis in cirrhotics (159). Features of DIC have been reported in cirrhotic patients with 
variceal haemorrhage, especially in those who die of continued bleeding (160), where 
multiple transfusions may be a confounding factor. However there is little evidence for DIC 
occurring as a primary event in cirrhosis (161). Moreover, another study found a strong 
association in 41 cirrhotic patients between endotoxaemia and high plasma levels of 
prothrombin fragment F1+2 and D-dimer (a pattern suggestive of secondary fibrinolysis), 
which interestingly then returned to normal after administration of  non absorbable antibiotics 
(162). A recent report showed a lower protein C activity in cirrhotics with severe sepsis as 
compared to those with non severe sepsis or without sepsis; this deficiency in protein C 
activity is associated with significant inflammatory response and DIC (163;164). 
 
 
Influence of infection on liver damage 
 
Normal liver microcirculatory function is maintained by a balance of vasoconstrictors (ET-1) 
and vasodilators (NO, carbon monoxide) (141). Both endotoxaemia and cytokines such as 
TNF-α and IL-1 cause hepatic necrosis by disruption of the microcirculation (165-168), the 
alteration in microcirculation due to endotoxin being mediated via Kupffer cells (169).  
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Endotoxin leads to the activation of Kupffer cells and the subsequent release of cytokines that 
worsen liver failure in several experimental models of liver failure (170-172). This production 
of proinflammatory cytokines and prostaglandins leads to infiltration of leukocytes and then 
liver failure (93). LPS has also been found to induce a marked influx of activated neutrophils 
into the liver. These are a source of reactive oxygen species (173), which are also triggered by 
LPS itself, as well as nitrogen species (174) leading to lipid peroxidation in the liver and 
secondary damage to hepatocytes. 
 
Kupffer cells play a pivotal role in endotoxin-induced hepatic injury (175-177). LPS triggers 
production of IL-1β, TNF-α, IL-12, IL-18 from Kupffer cells, IFN-γ from hepatic 
lymphocytes, and induces Fas-Ligand on the surface of NK cells, all leading to hepatic injury 
(178). TNF-α is hepatotoxic in itself, inducing the apoptosis of hepatocytes (179;180). LPS-
induced liver failure in mice is prevented by inhibition of NF-kB, thereby decreasing cytokine 
production (181). In addition, hepatocytes have membrane receptors for both endotoxin and 
the lipid A component of LPS, thus offering another possible pathway for liver injury (172). 
 
Antibiotic treatment prevents early liver injury caused by ethanol in rats (182) and both 
cisapride and antibiotics improve liver function in cirrhotic patients (56), strongly suggesting 
that bacterial products via translocation can worsen liver function. 
 
Other clinical evidence also suggests that liver function may be worsened by bacterial 
infections. Indeed, infections can aggravate liver dysfunction in patients with cirrhosis 
(26;183) and severe liver failure occurs in most patients with cirrhosis and septic shock  
(109;184;185). Thus sepsis may affect liver function independent of its haemodynamic 
effects.  
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Clinical evidence linking bacterial infection to variceal haemorrhage 
 
Bacterial infections are frequently associated with upper gastrointestinal (GI) bleeding in 
cirrhotic patients (18;183;186;187), developing in up to 66 % (20 % within the first 48 hours, 
35-66 % within 2 weeks) (2;18;188;189). About two thirds of these infections are present at 
hospital admission, while the remaining third develops during admission (3). Moreover, 
bacterial infections are more common in cirrhotic patients with acute variceal bleeding than in 
those admitted to hospital with other forms of decompensation such as encephalopathy 
(3;190). 
Our group showed that proven bacterial infection, or a surrogate of its presence, use of 
antibiotics, had the strongest independent association with failure to control bleeding in 
cirrhotic patients with variceal bleeding, even stronger than active bleeding at endoscopy and 
severity of liver disease (21). Recently a prospective survey of 1037 cirrhotics reported that 
the 297 with proven infection had a fourfold increase in the incidence of GI bleeding (8 % vs 
2 %, p<0.001) compared to 346 known not to have bacterial infection, and that infection was 
independently associated with the occurrence of GI haemorrhage (191). 
The strong association between infection and variceal bleeding in cirrhotics has been 
confirmed in several studies: association with failure to control bleeding (21;192), early 
rebleeding (2;191;193) and mortality (192). 
Two meta-analyses have shown that antibiotic prophylaxis prevents infections in cirrhotic 
patients with gastrointestinal bleeding and significantly increases the short-term survival rate 
(80;187). The improvement in mortality is equivalent to that seen with terlipressin (194). In a 
very recent randomised study of 120 patients prophylactic ofloxacin compared to on demand 
antibiotics was shown to prevent early rebleeding (24 % vs 64 %, p<0.01) and to decrease the 
amount of blood transfused (1.40±0.89 vs 2.81±2.29 units, p<0.05), in addition to preventing 
bacterial infections (22). Therefore, since our hypothesis was published (59), there are now a 
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number of publications strongly suggesting a causal link between the presence of an infection 
and the initiation of acute variceal bleeding and its associated early rebleeding, and supporting 
our hypothesis. 
 
Worsening of liver function is a recognized risk factor for first variceal bleeding (195), so that 
infection might contribute to this risk, or indeed be a trigger for variceal haemorrhage, 
particularly as the liver damage occurring in sepsis may itself contribute to an acute increase 
in portal hypertension. 
 
The risk for portal hypertensive related bleeding in cirrhotic patients is related to the degree of 
portal hypertension, liver dysfunction and to the size and endoscopic appearance of varices 
(195). However trigger factors are not known. In the setting of portal vein thrombosis in non 
cirrhotic patients, where often there are oesophageal varices of the largest size with red signs, 
the incidence of bleeding is much lower than in cirrhotics with similar varices (196). Thus the 
bleeding rate in portal vein thrombosis has been documented as 12,5 episodes per 100 patient 
years (197;198), whereas the risk of first bleeding with Child grade A cirrhotics with large 
varices and moderate red signs is 24 % in 1 year and in Child grade C with small varices and 
no red signs it is 20 % (195). 
 
The difference probably lies in the presence of liver disease (although the thrombophilic 
conditions often associated with portal vein thrombosis cannot be discounted). Cirrhosis 
predisposes to risk of infection, which is not reported in non-cirrhotic portal hypertension. In 
particular bacterial translocation is much less frequent in rats with portal vein ligation as 
compared to cirrhotic rats (64;65). 
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This increased release of endotoxin and viable bacteria into the portal and systemic circulation 
is closely related to liver cirrhosis, with portal hypertension and liver dysfunction influencing 
increased intestinal permeability and altered small bowel motility on the one hand and 
bacterial overgrowth on the other (Figure 1). The low grade endotoxaemia leads to the 
priming of monomacrophages and an increase of NO and TNF-α. Bacterial translocation 
causes a further increase in NO and TNF-α, a reduced response to vasoconstrictors and an 
increased risk of bacterial infection, with the associated risk of variceal bleeding, renal failure, 
hepatocellular injury, hepatic encephalopathy and mortality (Figure 2). 
 
The possible causative role of bacterial infection in variceal haemorrhage, is less easily 
understood, but nevertheless is most intriguing (59). Indeed, the known risk factors for 
variceal bleeding (HVPG, liver function, size of varices and presence of red signs) do not 
readily explain why bleeding and early rebleeding occur unpredictably in patients with 
cirrhosis. Portal pressure rises significantly with daily meals as well as exercise (199;200), yet 
despite these marked daily changes bleeding episodes are relatively infrequent. Thus a merely 
mechanical understanding of variceal bleeding as a consequence of portal pressure and 
tension on the variceal wall does not in our view explain the pattern of variceal bleeding. 
Endotoxaemia secondary to bacterial infection may indeed be the critical trigger for variceal 
haemorrhage (59), since it produces a wide series of effects that may predispose the cirrhotic 
patient to bleeding: impairment of primary and secondary haemostasis, increase of portal 
pressure and worsening of liver function (Figure 3). 
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METHODOLOGICAL STUDIES REGARDING 
THROMBOELASTOGRAPHY 
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THE EFFECTS OF UNFRACTIONATED HEPARIN, LOW MOLECULAR WEIGHT 
HEPARIN AND DANAPAROID ON THE THROMBOELASTOGRAM (TEG): A 
COMPARISON OF STANDARD AND HEPARINASE MODIFIED TEG WITH 
CONVENTIONAL COAGULATION ASSAYS 
 
 
 
Introduction 
 
Thromboelastography, developed in 1948 (201), has been used extensively as a research tool 
and more recently has been employed during liver transplantation and cardiac surgery to 
assess coagulation and guide blood product replacement in the peri-operative period (202-
204). The initial unpopularity of TEG as a coagulation test was in part due to the poor 
understanding of how variables in the coagulation system affecting the TEG, how these 
variables correlate with other more conventional clotting tests and how the procedure should 
be standardised (205-207). More recently, a number of studies re-investigating the properties 
of the TEG have been published, prompted by the increasing use of the TEG in clinical 
practice (208-214). 
 
Thromboelastography provides a global and dynamic assessment of coagulation that is not 
addressed by most conventional laboratory coagulation tests (215). Conventional assays 
terminate with the formation of a fibrin clot, and hence possess a well-defined end point 
which is easily standardised. Different parts of the clotting cascade are artificially isolated in 
these assays, and therefore they tend not to reflect other haemostatic abnormalities that might 
interfere with the formation of a stable fibrin clot, such as for example impaired platelet 
function. In contrast, TEG starts to generate data at the point at which fibrin strands begin to 
form, and as such is a more dynamic and global investigation, with multiple measurable 
endpoints (216). This reflects the interaction between platelets, the clotting cascade and 
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fibrinolysis. TEG is sensitive to qualitative and some quantitative differences in platelets, 
proteins of the clotting cascade and fibrinolysis (217;218).  
 
The TEG trace can be modified by several factors, but because of the increasing use of TEG 
during surgical procedures in which the administration of heparin is routine, the effects of 
heparin and heparin-related compounds have been the most widely studied (219-224). 
Commercially available TEG cuvettes coated with heparinase I can be used to inactivate 
heparin and other glycosaminoglycans (GAGs) such as heparan sulphate, for the assessment 
of TEG in patients who have received heparin (225-228). However, little data has been 
published regarding the correlation between the variables of the standard and heparinise-
modified TEG with conventional clotting tests. The present in vitro study was divided into 
two parts: in the first part, the sensitivity of standard TEG parameters was compared with 
conventional assays of coagulation for the detection of unfractionated heparin (UFH), low 
molecular weight heparin (LMWH) and Danaparoid in whole blood, over the concentration 
range of 0.025 – 1 U/ml. In the second part, the sensitivity of heparinise-modified TEG 
parameters was compared with the standard (unmodified) TEG and conventional assays of 
coagulation, for the detection of very low concentrations of UFH, LMWH and Danaparoid 
(concentration range of 0.005 – 0.05 U/ml).  
 
 
Materials and Methods 
 
Heparins and Danaparoid 
Unfractionated heparin (UFH) was supplied by CP Pharmaceuticals Ltd., Wrexham, UK. Low 
molecular weight heparin (LMWH) – Dalteparin (Fragmin®) was supplied by Pharmacia & 
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Upjohn, Milton Keynes, UK. Danaparoid (DPD) – Orgaran® was supplied by B & S Durbin 
Ltd., Middlesex, UK. 
 
Subjects 
This study was performed as part of a larger ongoing study of Thromboelastography in 
various medical disorders, which has been approved by the local research ethics committee 
(LREC) of the Royal Free Hospital. Blood samples were taken from ten healthy male 
volunteers for each part of the study.  For all subjects, baseline haemoglobin, white cell count, 
platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin 
time (TT), reptilase time, anti-Xa activity, standard TEG and heparinase I modified TEG were 
all within the reference ranges for these investigations.  
 
Blood sampling 
Blood samples were collected into plastic 10ml Sarstedt Monovette vacuum tubes 
containing sodium citrate solution (final concentration 0.106 M), using a 19G needle and no 
tourniquet. In the first part of the study, a 10u/ml solution of LMWH, UFH or Danaparoid 
was diluted 1/10 with citrated whole blood, and serial dilutions were made using citrated 
blood to achieve final concentrations of 1.0, 0.5, 0.25, 0.1, 0.05 and 0.025 U/ml. Control 
samples were prepared for three subjects using an equal volume of 0.9% (isotonic) saline 
instead of heparin / Danaparoid and diluting with citrated blood using the same protocol. This 
was in order to exclude a dilutional effect on blood coagulability from the addition of these 
drugs, and to determine the stability of the sample over the time from phlebotomy to 
completion of all TEGs. In the second part of the study, serial dilutions of LMWH, UFH or 
Danaparoid were made to final concentrations of 0.05, 0.025, 0.010 and 0.005 U/ml. After 
phlebotomy, all samples were allowed to stabilise in citrate for at least one hour prior to TEG 
analysis (229;230). 
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Thromboelastography 
Disposable standard and heparinase I coated plastic cuvettes and pins were supplied by 
Medicell UK (for Haemoscope Corp., Skokie, IL). Two Haemoscope Thromboelastograph 
coagulation analysers were used for this study. 20µl of 30mmol calcium chloride were added 
to a 340µl aliquot of test blood (total volume 360µl) in the cuvette to reverse citrate chelation, 
and mixed by raising and lowering the TEG pin three times. A thin film of mineral oil was 
floated on the surface of the blood to prevent evaporation during analysis. The cuvettes were 
pre-heated to 37°C in the analyser. 
 
In the first part of the study, TEGs on saline and heparin / Danaparoid spiked samples from 
the three control subjects were performed in parallel at each concentration. Standard and 
heparinise-modified TEGs for each sample dilution in the second part of the study were also 
performed in parallel. Tracings were recorded and analysis stopped once the tracing had 
reached the maximum amplitude, or after 60 minutes if a straight-line trace was produced. 
Clot retraction and fibrinolysis were not assessed in this study. TEG variables assessed were 
reaction time (R-time), clot formation time (K-time), clot formation rate (α-angle) and 
maximum amplitude (MA) (Figure 4). A value of 60 (minutes) for R-time and K-time, and 0 
(degrees) for α-angle and 0 (mm) for MA were assigned arbitrarily to straight-line traces. 
Reference ranges for these variables were obtained from Medicell UK (for Haemoscope 
Corp., Skokie, IL, based on a normal population mean +/- 2 SD), and were confirmed by our 
own in-house assessment of 20 normal subjects from the local population.  
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Other coagulation assays 
In addition to a TEG, the PT, aPTT, TT, and anti-Xa activity were determined for each 
sample. A reptilase time was also performed on samples from three control subjects to 
confirm that abnormalities of coagulation in the test samples were due to heparin and not an 
intrinsic abnormality of coagulation. Approximately 2.5ml blood from each sample dilution 
was centrifuged at 1200g for 12 minutes at 4C, the plasma aspirated and re-centrifuged for a 
further 12 minutes. The supernatant plasma was frozen at -40°C until testing. Clotting times 
were assayed using standard techniques, with an IL-Futura® Coagulation Analyser from 
Instrumentation Laboratories, Warrington, UK. Anti-Xa activity was determined using a 
chromogenic assay (Sigma Diagnostics, UK).  
 
Statistical analysis 
Descriptive statistics for all TEG and conventional test parameters are expressed as the mean 
± the standard error of the mean (SEM). The change in each TEG parameter vs. concentration 
(for both parts of the study) was analysed by calculating a summary slope of each parameter 
for each individual subject, and then assessing the mean of the summary slopes with a two-
tailed t-test. The correlation between TEG parameters and conventional coagulation assays 
was evaluated by comparing means of summary slopes using Pearson’s correlation 
coefficients. 
 
For the second part of the study looking at low concentrations (0.005-0.05 U/ml) of heparins 
and Danaparoid, the effect of heparinase on each TEG parameter at each concentration was 
evaluated using a paired two-tailed t-test. In order to compare the sensitivity of heparinise-
modified thromboelastography with the anti-Xa assay for detecting differences between 
concentrations of heparins and Danaparoid in the range 0.005-0.05 u/ml, two-tailed p-values 
were calculated using mean summary slopes for the difference between heparinase-modified 
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and standard TEG parameters vs. concentration, which were compared with p-values 
calculated from anti-Xa summary slopes. All calculations were performed with SAS for 
Windows version 8.02 and Microsoft Excel 2000. 
 
 
Results 
 
Tables 1a and 1b show the mean ± the standard error (SEM) for each TEG parameter and 
conventional assay performed in ten subjects for the first part of the study (concentrations of 
heparins and Danaparoid 0.025-1.0 U/ml). The mean ± SEM of standard and heparinise-
modified TEG parameters and conventional tests performed in ten subjects from the second 
part of the study (concentrations of heparins and Danaparoid 0.005-0.05 U/ml) are presented 
in Table 2. Values outside the normal range are underlined in both tables. In the both parts of 
the study, the addition of UFH, LMWH or Danaparoid to citrated whole blood resulted in 
prolongation of the R-time and K-time, and reduction in the α-angle and MA of the standard 
TEG compared with control samples. The highest concentration of each anticoagulant (1.0 
U/ml) produced a straight-line trace for up to 60 minutes, demonstrating complete inhibition 
of fibrin formation.  TEG parameters were within the reference range for all saline control 
samples. 
 
The results indicate that measurable differences in TEG parameters occurred at lower 
concentrations of UFH, LMWH and Danaparoid than standard PT, aPTT and TT assays were 
able to detect. In the first part of the study, concentrations of all three anticoagulants of less 
than 0.1 U/ml were undetectable by PT, aPTT or TT assays, but caused a reduction in the MA 
of the TEG for all three anticoagulants (Tables 1A and 1B). The K-time was prolonged by 
LMWH at 0.025 U/ml, but not by UFH or Danaparoid at this concentration. In the second part 
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of the study examining low concentrations (0.005-0.05 U/ml) of heparins and Danaparoid, the 
PT, aPTT and TT were within the reference range for all samples, but there was still a 
reduction (outside the reference range) in the MA of the TEG at concentrations of UFH of 
0.025 U/ml, and concentrations of LMWH and Danaparoid down to 0.005 U/ml (Table 2). 
The K-time was prolonged by LMWH at concentrations of 0.005 U/ml, by Danaparoid at 0.01 
U/ml, and UFH at 0.05 U/ml. Overall, the R-time and α-angle were the least sensitive of the 
TEG parameters in this study. 
  
In the first part of the study, the variation in all four TEG parameters was concentration 
dependent over the range 0.025 to 1.0 U/ml, for all three anticoagulant drugs (p<0.0001) 
(Table 3A). In the second part of the study, the concentration dependent variation in all four 
TEG parameters due to UFH over the range 0.005 to 0.05 U/ml was still significant (p<0.02), 
but changes in TEG parameters caused by LMWH or Danaparoid were not significant at these 
low concentrations (Table 3B). Overall, there was no correlation between TEG parameters 
and the conventional clotting assays over the entire concentration range of 0.005 to 1.0 U/ml 
for any of the anticoagulants studied. 
 
TEG parameters were within the reference range for all tests performed in heparinase I coated 
cuvettes in the second part of this study, suggesting that the enzyme had successfully 
neutralised the anticoagulant effect of all three drugs. ‘Heparinase-modified’ TEG parameters 
were calculated as the difference between TEG parameters recorded from aliquots of the same 
blood sample tested in standard and heparinase I coated TEG cuvettes in parallel.  All four 
heparinise-modified TEG parameters were significant at the lowest concentration of LMWH 
and Danaparoid studied (0.005 U/ml; p<0.05) (Table 2). In contrast, only the heparinise-
modified K-time and α-angle were significantly sensitive to UFH at this concentration. 
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Heparinase-modified TEG parameters were further compared with the sensitivity of the anti-
Xa assay for distinguishing between concentrations of all three anticoagulants over the range 
0.005 to 0.05 U/ml. In addition to significantly detecting the lowest concentration of UFH 
studied (0.005 U/ml), the heparinise-modified K-time and α-angle of TEG were found to be 
more sensitive at distinguishing between concentrations of UFH across the range 0.005 to 
0.05 U/ml than the anti-Xa assay (p<0.01 vs. p=0.43). In contrast, the opposite was observed 
with LMWH and Danaparoid over this concentration range (p<0.05 for anti-Xa vs. p>0.1 for 
heparinise-modified TEG) (Table 4). The results suggest that at low concentrations of UFH, 
heparinise-modified thromboelastography may be more sensitive than the anti-Xa assay for 
detecting differences between small amounts of UFH in blood samples.  
 
The clotting activity of citrated blood samples did not deteriorate significantly with storage 
for several hours prior to analysis, as demonstrated by the preservation of TEG parameters 
within the reference range over time for saline control samples. These controls also confirmed 
that observed effects on TEG or coagulation assays were not due to haemodilution from the 
addition of heparin / Danaparoid to blood samples. Reptilase times performed in three control 
subjects were within the reference range (results not shown), confirming that changes in TEG 
and coagulation parameters in this study were due to the addition of heparin / Danaparoid. 
 
Finally, it is of note that UFH, LMWH and Danaparoid significantly prolonged the aPTT at 
concentrations similar to those expected in vivo when prophylactic doses are administered 
subcutaneously (i.e. approximately 0.3 u/ml). Unfractionated heparin given subcutaneously 
might prolong the aPTT at this concentration, but prophylactic doses of LMWH should have 
little or no effect on the aPTT. This discrepancy probably results from the in vitro addition of 
these drugs to blood samples in what would be equivalent to an intravenous route of 
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administration in vivo, and increased relative bioavailability of each anticoagulant due to the 
absence of endothelial cell binding. 
 
 
Discussion 
 
The TEG is increasingly used in surgery to detect global coagulation changes and guide blood 
product replacement peri-operatively. Most experience to date has been achieved during 
hepatic and cardiac surgery (231-234), but the use of TEG in other settings is also increasing 
(235). The observation from the present study that TEG is extremely sensitive to very small 
quantities of UFH, LMWH and Danaparoid in whole blood is significant, because many 
patients undergoing surgery receive some form of heparin therapy or prophylaxis pre-
operatively (236;237). Moreover, the implication from this and other studies is that even the 
minute quantities of heparin often used to flush intravenous catheters may also affect TEG 
(238;239). Therefore, the reliability of the standard TEG as a guide for blood product 
replacement during surgery is limited by the possibility of heparin contamination. 
 
Heparinase I coated TEG cuvettes are commercially available, and it has been suggested that 
these should be used for all samples where there is a risk of heparin contamination (240). 
However, under conditions of endothelial stress such as surgery or sepsis, endogenous release 
of very small quantities of glycosaminoglycans (GAGs) such as Heparan Sulfate can occur in 
some patients (241).  There is also evidence that these GAGs can influence TEG, an effect 
that is reversed by the use of heparinase I coated TEG cuvettes (242-245). These findings are 
supported by the present study, where TEG changes due to minute quantities of Danaparoid (a 
combination of Heparan Sulfate, Dermatan Sulfate and Chondroitin Sulfate) were completely 
reversed by heparinase I. Endogenously released GAGs may be clinically significant in terms 
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of an increased bleeding risk for some patients (246;247), therefore eliminating this effect on 
TEG with heparinase and disregarding it as heparin contamination may ignore some clinically 
important information regarding blood coagulation. These limitations of the standard and 
heparinise-modified TEG make it very difficult to standardise the assay or to produce reliable 
guidelines for blood product replacement during surgery. Therefore, both standard and 
heparinase modified TEGs should be performed in parallel in all patients where there is a risk 
of heparin or GAG contamination, but the results should be cautiously interpreted in the 
context of each individual clinical setting.  
 
Inhibition of coagulation by UFH, LMWH and Danaparoid as measured by the TEG was 
shown to be concentration dependent over the range 0.025 to 1.0 U/ml, which is in agreement 
with the results of earlier studies (248;249).  However, the current study is the first to assess 
concentrations of UFH, LMWH and Danaparoid below 0.1 U/ml in an attempt to define a 
lower limit for this effect. While standard TEG changes due to UFH were significantly 
concentration dependant between 0.005 and 0.05 U/ml, this was not true for LMWH and 
Danaparoid. In addition, heparinise-modified TEG parameters were shown to be more 
sensitive to minute quantities of UFH than anti Xa activity, but less sensitive to LMWH and 
Danaparoid. The variable sensitivity of TEG parameters and conventional coagulation assays 
to the presence of low concentrations of UFH, LMWH and Danaparoid may reflect the 
different composition and mechanisms of action of these anticoagulants. UFH acts via 
potentiation of antithrombin in the inhibition of thrombin and factor-Xa (250), whereas 
LMWH predominantly inhibits factor-Xa (251). Both UFH and LMWH are excreted via the 
kidneys, but unlike LMWH, UFH also binds non-specifically to plasma proteins and 
macrophages, accounting for the variable in vivo activity that is often observed after 
administration of UFH to patients (252). Danaparoid is a mixture of 84% Heparan Sulphate, 
12% Dermatan Sulphate and 4% Chondroitin Sulphate. Whilst heparan sulphate acts via 
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antithrombin in the same way as UFH and LMWH (253), dermatan sulphate has a different 
mechanism of anticoagulation via potentiation of heparin cofactor II (254), and chondroitin 
sulphate is thought to be devoid of any anticoagulant activity (255). 
 
Zmuda et al commented that concentrations of Enoxaparin and Danaparoid resulting in 
‘minor’ prolongations of the aPTT (< 10s) markedly or completely inhibited coagulation as 
measured by TEG (256). The results of the current study support these findings, and similar 
observations have been made in a recent in vitro study of the effects of fondaparinux and 
enoxaparin on tissue factor-triggered thromboelastography (257). Since the generation of 
TEG is multifactorial and involves the entire blood coagulation system including platelets and 
fibrinogen (258;259), one may have expected TEG to be less sensitive to heparins and 
Danaparoid than the aPTT, because the aPTT analyses only a part of the coagulation cascade 
in isolation. 
 
In the current study there was no significant correlation between concentration dependant 
changes observed in TEG parameters compared with conventional coagulation assays, which 
is in contrast to the findings of previous in vivo studies (260-262). The absence of a 
correlation in the current study may reflect the in vitro addition of anticoagulants to blood 
samples and the wide range of concentrations of heparins and Danaparoid that were used 
(0.005 to 1.0 units/ml), since changes in the TEG parameters observed at low concentrations 
of each anticoagulant were not detected by the PT, aPTT and TT assays. 
 
Blood samples require 30-60 minutes standing time before processing in order to obtain 
reproducible TEG results (263;264). In addition, the large number of anticoagulant 
concentrations tested per subject in this study and the duration of each TEG (up to 60 
minutes) resulted in storage of blood in citrate for a significant period of time. There is 
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conflicting data as to whether citrate storage significantly affects TEG. Most studies agree 
that citration of blood does influence TEG, but there is conflicting data as to whether these 
changes are stable and lead to reproducible results. Roche et al (265) compared TEG 
parameters obtained by native blood, citrated blood stored at room temperature and citrated 
blood that had been refrigerated. They found that citration and recalcification of blood ‘pre-
activated’ the sample, and that refrigeration increased the magnitude of this effect. However, 
this study was performed on blood samples taken on different days from a very small number 
of subjects (five). Other studies performed on blood from patients with liver disease (266) or 
undergoing surgery (267), have demonstrated that blood stored in citrate remains stable and 
produces reliable TEG tracings between one and eight hours after phlebotomy. These findings 
are supported by our study, where TEG parameters were preserved within the reference range 
for citrated saline control samples stored for up to seven hours before analysis. However, such 
arguments are more important for standardisation of TEG for use in clinical practice than to 
the results of the present in vitro study, where like samples were compared with like. 
 
In conclusion, the results demonstrate that measurable effects on variables of the standard 
TEG occur at much lower concentrations of UFH, LMWH and Danaparoid than conventional 
fibrin based PT, aPTT and TT assays are able to detect. Heparinase modification of TEG 
greatly increases the sensitivity of this assay for UFH, LMWH and Danaparoid, and was more 
sensitive to minute quantities of UFH than anti-Xa activity. 
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A COMPARISON OF KAOLIN- VERSUS NON KAOLIN-ACTIVATED 
THROMBOELASTOGRAPHY IN NATIVE AND CITRATED BLOOD 
 
 
 
Introduction 
 
Hartert first described thromboelastography (TEG) as a global test of blood coagulation in 
1948 (268). It enables a global and dynamic assessment of haemostatic function, as it 
evaluates the interaction of platelets with the protein coagulation cascade, starting from the 
initial platelet-fibrin interaction, through platelet aggregation, clot strengthening and fibrin 
cross-linkage and eventually clot lysis (269). 
 
This technique is increasingly used particularly in the setting of liver transplantation and 
cardiovascular surgery, as it allows for a rational guide to blood component replacement or 
treatment of fibrinolysis (270-275). However, the method has proven itself to be useful also in 
other settings such as trauma and obstetric emergencies (276-278). 
 
In research, this method has been of great value in the assessment of the role of bacterial 
infection in impairing coagulation in cirrhotic patients, possibly triggering variceal bleeding 
(279-284). 
 
TEG can be performed on native or citrated blood, the latter being a surrogate of native blood 
in healthy controls (285;286), surgical (287) and cirrhotic patients (288). However, because 
the generation of the thromboelastographic trace using calcium activated blood is slow, the 
addition of activators has been proposed to reduce the time to generate the trace, especially 
since the main clinical use of TEG is in an intraoperative or emergency setting and requires 
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rapid results. Kaolin is increasingly used as an activator for this purpose, substantially 
reducing the time to trace generation. 
 
Despite its increased use, only two studies have formally assessed the use of kaolin activated 
thromboelastography. Both of these studies evaluated surgical patients undergoing aprotinin 
treatment and compared kaolin-activated with celite-activated blood (289) or with celite- and 
tissue factor-activated blood (290). 
 
The aim of this study was to compare kaolin-activated thromboelastography with non kaolin-
acitvated thromboelastography in both native and citrated blood in patients with liver disease, 
patients undergoing anticoagulant treatment with warfarin or low-molecular weight heparin 
and healthy volunteers. We also intended to compare non-kaolin activated 
thromboelastograohy in native and citrated blood in this range of patients. 
 
 
Materials and methods 
 
We studied TEG blood and coagulation parameters in 21 healthy volunteers (Group 1) and 50 
patients, including 20 patients with liver cirrhosis with a non biliary aetiology, mainly alcohol 
and viral hepatitis (Group 2), 10 patients with primary biliary cirrhosis (PBC) or primary 
sclerosing cholangitis (PSC) (Group 3), 10 patients taking warfarin (Group 4) and 10 patients 
receiving enoxaparin prophylaxis for medical and surgical conditions (Group 5). All patients 
were inpatients admitted to the Royal Free Hospital. 
 
Informed consent was obtained, and the procedures followed in this study were in accordance 
with the regulations of the Local Research Ethics Committee of the Royal Free Hospital. The 
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selected subjects were not taking drugs known to affect coagulation parameters or platelet 
aggregation for at least 1 week before starting the study (with the exception of anticoagulants 
in Groups 4 and 5). 
 
A blood sample was taken by a single peripheral venepuncture from the antecubital fossa 
using a 21 gauge butterfly needle and a light tourniquet to avoid stasis or platelet activation. 
Blood was collected into plain tubes (native) and into 3 mL polypropylene tubes containing 
0.3 mL of 0.106M sodium citrate solution (citrated) (Sarstedt Monovette, Leicester,UK; 
9NC/10 ml tubes, nine parts venous blood to one part trisodium citrate) and gently inverted 
three times.  
The samples from all patients were evaluated by TEG using non kaolin-activated and kaolin-
activated native blood and non kaolin-activated and kaolin-activated citrated blood. TEG was 
performed using a computerized thromboelastograph (Haemoscope Corp., Skokie, Illinois, 
USA) as recommended by the manufacturer: 360 µL of native whole blood were pipetted into 
the warmed TEG cuvette (37°C) within 4 minutes of venepuncture. Citrated whole blood was 
stored at room temperature for 90 minutes as previously advised (286). After this time, 340 
µL of citrated blood were pipetted into the preheated cup containing 20 µL of 0.2M CaCl2 as 
activator. 
Kaolin (Haemoscope Corp, Skokie, Illinois, USA) was used as advised by the manufacturer. 
Kaolin vials were warmed to room temperature and 1 mL of the blood sample (native or 
citrated) was pipetted in to the vial. Blood and kaolin were mixed by inverting the vial five 
times. Subsequently, 360 µL of treated native blood were pipetted into the preheated cup. As 
for citrated blood, after 90 minutes 340 µL of treated citrated blood were pipetted into the 
preheated cup containing 20 µL of 0.2M CaCl2 as activator. 
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The principal variables analysed by the TEG analyser are (Figure 4): the reaction time (r), 
which represents the rate of initial fibrin formation and is related to plasma clotting factors 
and circulating inhibitor activity; the clot formation time (k), which represents the time taken 
by the forming clot to reach a fixed degree of viscoelasticity and is related to the activity of 
the intrinsic clotting factors, fibrinogen and platelets; the alpha angle (α), which represents 
the rate of clot growth and is mainly a function of platelets, fibrinogen and plasma 
components residing on the platelet surface; and the maximum amplitude (ma), which is a 
reflection of the absolute strength of the fibrin clot and is a direct function of the maximum 
dynamic properties of fibrin and platelet number and function (269). 
 
 
Statistics 
 
Spearman's test was used for assessing correlation of the TEG variables inbetween the 4 
different techniques with an r (correlation coefficient) value of ≥ 0.7 considered to be a good 
correlation; Wilcoxon’s matched pairs test was used for assessing differences in absolute 
values between native and citrated blood (GraphPad Prism version 4.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com). For analysis of 
differences between the groups the Kruskal-Wallis test was used. The Bland and Altman plot 
was used to assess the degree of agreement between the different techniques(291). 
 
 
Results 
 
We performed TEG on native and citrated blood, both with and without addition of kaolin as 
an activator, on 21 healthy volunteers and 50 patients. The healthy volunteers (13 males, 8 
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females) had a mean age ± S.D. of 31.8±4.7 years. Of the 50 patients, 28 were male and 22 
were female, and the mean age ± S.D. was 53.0±12.4 years. Details are listed in Table 5. In 
Group 2, the Child-Pugh score (mean±S.D.) was 9±1.8. In Group 4, the INR (mean±S.D.) 
was 3.0±1.0 and in Group 5, the enoxaparin daily dose was 20 mg in 4 patients and 40 mg in 
6 patients. 
 
Correlation between native blood and kaolin-acitvated native blood (Table 6) 
 
Considering both healthy volunteers and patients (Groups 1-5), there was a good correlation 
for the r time (r=0.70) and almost for the ma (r=0.69), but not for k time and α angle. 
Considering the single groups, in Group 1 (healthy volunteers) there was no good correlation 
with only the ma approaching an r value of 0.70 (r=0.69). In Group 2 (patients with non 
biliary cirrhosis), there was a good correlation only for the ma (r=0.77). In Group 3 (patients 
with primary biliary cirrhosis or primary sclerosing cholangitis) there was no correlation for 
any variable, with an almost inverse correlation for α angle (r=-0.68). In Group 4 (patients on 
warfarin treatment) there was good correlation for the r time (r=0.77) but not for the other 
variables. In Group 5 (patients on enoxaparin prophylaxis) there was good correlation for all 
variables: r time (r=0.90), k time (r=0.71), α angle (r=0.78) and ma (r=0.75). 
 
Correlation between citrated blood and kaolin-activated citrated blood (Table 7) 
 
Considering both healthy volunteers and patients (Groups 1-5), there was a good correlation 
only for ma (r=0.80) but not for the other variables. In Group 2 and 3, there was good 
correlation for ma (r=0.80 and r=0.77, respectively) but not for the other variables. In Group 
4, there was no correlation for any of the variables. In Group 5, there was good correlation 
only for the r time (r=0.73), but not for the other variables. 
 42
 
Correlation between native blood and citrated blood (non kaolin-activated) (Table 8) 
 
Considering both healthy volunteers and patients (Groups 1-5), there was a good correlation 
only for the ma (r=0.72), but not for the other variables. In Group 1 and Group 2, there was a 
good correlation only for the ma (r=0.71 and r=0.71, respectively). In Group 3, there was no 
correlation for any of the variables. In Group 4, there was good correlation only for the α 
angle (r=0.82). In Group 5, there was good correlation for all variables: r time (r 0.84), k time 
(r=0.90), α angle (r=0.82) and ma (r=0.75).  
Comparing absolute values (Table 9), there was a significative difference between native and 
citrated blood only for ma (p<0.05) when considering both healthy volounteers and patients. 
For healthy volounteers (Group 1), there was a significant difference for all variables, while in 
Group 2 this was present only for ma and in Group 4 for r time and k time. In Groups 3 and 5 
there was no difference between the two values for any variable. 
Considering both healthy volunteers and patients together, for all four TEG variables the 
Bland & Altman plots (Figure 5) did not suggest a systematic error as the mean was not 
significantly different from zero. However, for all four TEG variables, the differences within 
the mean and 1.96 times the standard deviation (2 SD) were clinically important and thus the 
agreement was not good. For all four TEG variables, the differences increased with the mean 
between the two techniques, suggesting the agreement is worse with increasing magnitude of 
measurement.  
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Changes in TEG between the different groups (Table 10) 
 
Considering non kaolin-activated native blood, the r time was not significantly different 
between groups, while k time and α angle was significantly different between groups 1 and 3 
and ma between groups 1 and 3, 1 and 5, 2 and 3 and 2 and 5. 
Considering kaolin-activated native blood, the r time was significantly different between 
groups 1 and 3, the k time and the α angle between groups 1 and 3, 1 and 5, 2 and 3, 2 and 5, 
and the MA between groups 1 and 5, 2 and 3, 2 and 4 and 2 and 5. 
Considering non kaolin-activated citrated blood, the r time was significantly different 
between groups 1 and 4, 3 and 4 and 4 and 5, the k time between groups 1 and 4 and 3 and 4, 
the α angle between groups 3 and 4, and the ma between groups 1 and 5, 2 and 3, 2 and 4 and 
2 and 5. 
 
 
Discussion 
 
We evaluated the correlation between kaolin-activated and non kaolin-activated 
thromboelastography (TEG) in a group of 21 healthy volunteers and a group of 50 patients 
with different types of altered haemostasis. Amongst these we considered patients with 
cirrhosis (who are known to have an impaired platelet function and number as well as an 
impaired coagulation (292)) and patients receiving anticoagulant treatment, either warfarin or 
low molecular weight heparin prophylaxis against deep vein thrombosis. We evaluated 
patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) as a 
separate group from patients with cirrhosis of non biliary aetiology, as the former seem to 
have a hypercoagulable state (293). 
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The results of this study do not show good correlation between the kaolin-activated and non 
kaolin-activated TEG for either native or citrated blood in both healthy volunteers and the 
different patient groups considered. The only good correlations were that between native and 
kaolin-activated native blood for r-time in patients on anticoagulant treatment and the ma in 
all correlations with the exception of Groups 3 and 4. Overall, correlation between kaolin-
activated and non kaolin-activated blood seemed to be better with native than with citrated 
blood. 
The use of kaolin as an activator for TEG has only been reported in two studies. Avidan and 
coworkers (290) found a good correlation between kaolin- and celite-activated TEG with 
regard to r-time, α angle and ma. Pivalizza and coworkers (289) found no statistically 
significant difference in TEG parameters between kaolin- and celite-acitvated TEG. Neither 
study compared kaolin-activated with non kaolin-activated TEG using either native or citrated 
blood. 
Surprisingly, the correlation between non kaolin-activated native and citrated blood was also 
unsatisfactory, with the exception of the group 5 and for the ma in all groups except the 
PBC/PSC and warfarin group. There was a statistically significant difference in the absolute 
values between native and citrated blood for all variables in healthy volounteers, for the ma in 
Group 2 and r-time and k-time in Group 4. 
Similar results to ours were found in two studies, one in 8 healthy controls (285) and one in 
90 surgical patients (287), which compared native and citrated blood samples. The first study 
(285) did not find any statistical difference comparing all the TEG variables between native 
and citrated blood. In the second study (287) TEG variables in citrated blood were different 
from those in native blood but remained stable between 1 and 8 hours. However, in this 
surgical study all subjects had both normal coagulation and platelet counts; citrated blood was 
used with celite, a potent activator of coagulation.  
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Another study, from our group (286), compared TEG parameters of native blood to those of 
recalcified citrated blood without celite in 10 healthy subjects. In this study, a significant 
difference was found between citrated and native blood between 60 and 120 minutes for r-
time, k-time, α angle and ma. Our current findings in the group of healthy volunteers 
substantially confirm these previous results with the exception of a significant shortening of 
the r-time with citrated blood (Table 10). 
Non kaolin-activated native blood was compared to non kaolin-activated citrated blood in 
patients with liver disease in a previous study from our group, involving 32 patients with 
cirrhosis or liver failure (288), with no significant difference found for all the variables. Again 
we found similar results in our current study, with the exception of a significantly greater ma 
in the citrated blood, confirming our previous findings in patients with cirrhosis of a non-
biliary origin. Why TEG with native blood is different to TEG with citrated blood in healthy 
volounteers but apparently not in cirrhotics remains unexplained. 
In the current study we evaluated changes of both kaolin- and non kaolin-activated blood in 
both native and citrated blood between the different groups in order to assess if the different 
techniques resulted in different changes in different clinical settings. Non kaolin-activated 
native blood results were different between healthy volunteers and PBC/PSC patients, the 
latter showing an expected hypercoagulability (293). Kaolin-activated native blood values 
were also different between healthy volunteers and PBC/PSC patients (again showing a 
hypercoagulable state in the latter), but there were also differences between healthy volunteers 
and patients on enoxaparin prophylaxis (surprisingly showing hypercoagulability in the 
enoxaparin group), between patients with cirrhosis and PBC/PSC patients (hypercoagulability 
in the latter), and lastly between patients with cirrhosis and patients on enoxaparin 
prophylaxis (again with hypercoagulability in the latter). Interestingly, non kaolin-activated 
citrated blood values were markedly different between patients on warfarin and healthy 
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volunteers (the former being less coagulable as expected) and PBC/PSC patients (the warfarin 
group again being less coagulable).  
However, none of the methods gave significantly different values between healthy volunteers 
and patients with cirrhosis. Overall, the ma was the variable with the best discriminating 
potential. This was true especially for the kaolin-activated samples, in which the r-time values 
had little discriminative value between the groups. This may reflect the normal thrombin 
generation recently described and commented on in cirrhosis (294). With non kaolin-activated 
native blood healthy volounteers seemed to coagulate tendentially less than cirrhotics while 
with non kaolin-activated citrated blood the opposite seemed to be the case, even though the 
differences were not statistically significant. Our sample might have been too small to detect a 
statistically significant difference between these groups as patients with cirrhosis are very 
heterogeneous in terms of their haemostatic disturbances (alterations of platelet number and 
function, reduced synthesis of clotting factors, hyperfibrinolysis) and thus any differences 
might have been masked by the heterogeneity in our limited sample. 
Again, TEG with non kaolin-activated citrated blood seems to be the only technique to detect 
a significantly impaired coagulation in the warfarin group as compared to healthy volunteers. 
The enoxaparin group also coagulates tendentially less only with this technique, even though 
again the differences were not statistically significant. Indeed, the apparent hypercoagulability 
of the enoxaparin group with the other two techniques is surprising, and might be due to the 
underlying medical conditions that led to the initiation of enoxaparin prophylaxis. Another 
possible explanation for the lack of hypocoagulability on TEG shown in the warfarin and 
enoxaparin group might be the age difference (31.8±4.7 in Group 1 and 55.2±17.5 and 
55.8±15.9 in Groups 4 and 5, respectively), as increasing age seems to be associated with 
hypercoagulability (295). 
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One more interesting finding was the confirmation of the presence of hypercoagulability in 
the PBC/PSC group, with a markedly prolonged ma as compared to patients with non 
PBC/PSC cirrhosis, suggesting a difference in platelet function between these patients (296). 
In conclusion, we found a poor correlation between kaolin-activated and non kaolin-activated 
thromboelastography in both healthy volunteers and patients with a wide range of conditions 
affecting coagulation. Moreover, there was poor correlation between native and citrated blood 
with non-kaolin activated blood. The ability of TEG with non kaolin-activated citrated blood 
to detect changes in patients receiving warfarin, and the ability of TEG with kaolin-activated 
blood to detect changes in patients having enoxaparin-induced anticoagulation deserves to be 
investigated further.  
The lack of a standard reference in the literature for TEG and the results of this study do not 
give grounds as to which technique to use. It is clear that any TEG study should at least have 
its own internal control, e.g. if kaolin activation is used, then have non kaolin-activation. 
Kaolin-activated blood is extensively used in intensive care, but most published comparative 
data is only available for non-kaolin activated blood. Further studies investigating the 
correlation between these different techniques when used in different clinical settings are 
needed. Meanwhile, the TEG methodology should be carefully noted when comparing 
different studies. 
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CLINICAL STUDIES USING THROMBOELASTOGRAPHY 
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ENDOGENOUS HEPARINOIDS IN ACUTE VARICEAL BLEEDING 
 
 
 
Introduction 
 
Bleeding from gastrooesophageal varices is the most common source of bleeding in cirrhotics. 
The risk of variceal bleeding is associated with the severity of liver dysfunction, large varices, 
endoscopic red signs on varices and portal pressure. However, why bleeding occurs 
unpredictably and infrequently in individual patients considering the frequent daily changes in 
portal pressure is unknown.  
Bacterial infections occur in 35-66 % of cirrhotics presenting with gastrointestinal bleeding 
(187). We have proposed a causal relationship between variceal bleeding and bacterial 
infection, the latter acting as a trigger (59). The possible pathophysiological basis is 
endotoxin-induced endothelin release and subsequent increase in intrahepatic resistance (via 
hepatic stellate cell contraction) and consequent rise in portal pressure, combined with 
impairment of haemostasis by inhibition of platelet aggregation due to endotoxin-induced 
nitric oxide and prostacyclin (59). 
We have shown a heparin effect using heparinase I-modified thromboelastography (TEG) a 
highly sensitive method for detecting heparin-like activity, in infected cirrhotics (23), and in 
another study anti-Xa activity was detected in several but not all patients who had the heparin 
effect (297). The infected patients already had infection present for several hours, before 
presenting to the hospital when the TEG was performed. 
We describe the first two cirrhotic patients with endoscopically confirmed variceal 
haemorrhage who bled whilst in hospital, studied immediately after the first episode of 
haematemesis.  
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Patients and methods 
 
Patient 1 was a 66 year old caucasian male and patient 2 a 42 year old black female, both with 
alcoholic cirrhosis. Patient 1 had Child-Pugh grade C, patient 2 Child-Pugh Grade B cirrhosis. 
Both patients had endoscopic banding and intravenous terlipressin and received therapeutic 
doses of intravenous cefotaxime for prophylaxis of bacterial infections as currently 
recommended (187). Informed consent was obtained for taking multiple blood samples (with 
prior approval of the protocol by the Ethics Committee) for Heparinase I-modified TEG and 
anti-Xa activity assay. The baseline samples were taken before administration of colloid, 
blood products or antibiotic therapy, and then at subsequent times over 7 days. Heparinase I-
modified TEG (Haemoscope Corp., Skokie, IL) was performed in one channel whilst 
simultaneously perfoming a standard TEG in the second channel using calcium-activated 
citrated blood from the same sample 90 minutes after venepuncture, as we have previously 
shown that citrated blood can substitute native blood in cirrhotic patients (288). Anti-Xa was 
assessed by chromogenic assay (Sigma Diagnostics, Poole, Dorset, UK) and by clotting assay 
(Diagnostic Reagents, Thame, Oxford, UK). A heparin effect was defined as an improvement 
of r time, k time and α angle occurring together in Heparinase I-modified TEG as compared 
to the standard TEG. Informed consent was obtained from each patient included in the study 
and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki 
as reflected in a priori approval by the local ethics committee. 
 
 
Results 
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A heparin effect (Figure 6) was detected between 1 hour (patient 2) and 6 hours (patient 1) 
after the initial bleeding episode and persisted for 6 to 7 days, not corrected by administration 
of fresh frozen plasma and/or red blood cells (Figure 7). In patient 1 anti-Xa activity was 
positive during the same time span during which there was a heparin effect. Baseline urine, 
blood and ascites cultures were negative in both patients, and neither developed infections 
subsequently. 
The TEG parameters worsened immediately after the bleeding episode: in patient 1, r time 
from 11 minutes (4 hours after the bleeding episode) to 18.8 minutes (10 hours after the 
bleeding episode), k time from 2.7 minutes to 7.3 minutes, α angle from 53.8 ° to 28.7 °. In 
patient 2 r time from 11.2 minutes (1 hour after the bleeding episode) to 33.8 minutes (3 hours 
after the bleeding episode), k time from 3.1 minutes to 10.7 minutes, α angle from 50.8 ° to 
17.8 °. These values slowly returned to normal concomitantly with the disappearance of the 
heparin effect after 6 to 7 days: r time 11 minutes in patient 1 and 16.2 minutes in patient 2, k 
time 3.5 minutes in patient 1 and 4.4 minutes in patient 2 and α angle 43.6 ° in patient 1 and 
42.2 ° in patient 2. 
The worsening of the TEG parameters was only partially corrected by the administration of 
fresh frozen plasma and/or red blood cells (Figure 2). Both patients received all their blood 
products within the first 24 hours. The greater amount of blood products given in patient 1 (6 
units of packed red cells and 4 units of fresh frozen plasma) probably prevented the worsening 
of TEG parameters to the degree seen in patient 2 (who only received 2 units of fresh frozen 
plasma), but in neither patient did the TEG parameters return to the baseline values nor the 
heparin effect disappear. The routine coagulation parameters (PT, aPTT) did not show any 
correlation with the worsening TEG parameters or the heparin effect. 
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Discussion 
 
We have shown the presence of endogenous heparinoids, and their disappearance over several 
days for the first time in cirrhotic patients with acute variceal bleeding. There was no 
evidence of infection, but the antibiotic prophylaxis possibly prevented or treated infection. 
Neither patient experienced early rebleeding. The heparin effect was documented shortly after 
the beginning of the haemorrhage and disappeared over 5 days over the same time course of 
antibiotic therapy. This was also seen by Montalto et al (23). The absence of a heparin effect 
at the beginning of bleeding and appearance thereafter could suggest that bleeding is a cause 
of its manifestation, but in addition the heparin effect needs to be compared in native as well 
as citrated blood as the citrate may mask an initial heparin effect. The heparin effect could 
influence continued variceal bleeding or early rebleeding. It is possible that the heparin effect 
might be worse in the absence of antibiotics. This phenomenon deserves wider study, 
particularly as bacterial infection has been linked to failure to control variceal bleeding and 
early rebleeding, in a randomised study of prophylactic antibiotics (22). 
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HEPARIN EFFECT ON THROMBOELASTOGRAPHY AFTER TIPS PROCEDURE 
 
 
 
 
 
Introduction 
 
 
Bacterial infections are a common and severe complication in hospitalized patients with 
decompensated cirrhosis and are frequently associated with upper gastrointestinal (GI) 
bleeding and other complications of portal hypertension (298). 
 We have previously reported that proven bacterial infection, or a surrogate of its presence, 
use of antibiotics, had the strongest independent association with failure to control bleeding in 
cirrhotic patients with variceal bleeding (21). The strong association between infection and 
variceal bleeding in cirrhotics has been confirmed in several studies: association with failure 
to control bleeding (21;192), early rebleeding (21) and mortality (192). A recent meta-
analysis confirms that antibiotic prophylaxis prevents infections in cirrhotic patients with 
gastrointestinal bleeding and significantly increases the short-term survival rate (80). In a 
recent randomised study of 120 patients prophylactic ofloxacin compared to on demand 
antibiotics was shown to prevent early rebleeding and to decrease the amount of blood 
transfused, in addition to preventing bacterial infections (22). This has been confirmed in 
another randomized study (299). Therefore, since our hypothesis was published (59), there are 
now a number of publications which support it, suggesting a causal link between infection and 
variceal bleeding. 
How bacterial infection might worsen or be a trigger for variceal haemorrhage, is still under 
study (59). Using thromboelastography (TEG), we previously showed impaired coagulation in 
cirrhotic patients with bacterial infection (145) and the presence of a heparin effect on 
heparinase I-modified TEG in the same setting (23), which was subsequently found to be 
associated with the presence of anti-Xa activity (297) (suggesting the presence of endogenous 
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heparinoids). We also reported the presence of a heparin effect immediately after variceal 
bleeding in cirrhotic patients (300).  
Endotoxin or cytokines could release heparinoids from endothelium in a dose-dependent 
manner (23) and mast cell activation due to bacterial infection could also release heparin. 
Higher endotoxin concentrations are found in peripheral blood of cirrhotic patients than in 
normal subjects (32) with a statistically significant gradient between portal and peripheral 
blood (33), highlighting the role of the bowel as the source of endotoxin. 
During a transjugular intrahepatic portosystemic shunt (TIPS) procedure, a shunt is created 
between the portal and the systemic circulation with an inflow of portal blood into the 
systemic circulation bypassing the liver. 
The aim of our study was to assess the presence of a heparin effect on heparinase I-modified 
TEG in patients undergoing a TIPS procedure, both before and after the procedure. Our 
hypothesis was that given the presence of a portosystemic gradient of endotoxaemia, and the 
role of endotoxaemia and bacterial translocation on the release of heparinoids and the 
subsequent worsening of coagulation as shown by TEG, the inflow of portal blood unfiltered 
by the liver after a TIPS procedure might show the presence of the heparinoids in the portal 
blood through a heparin effect on TEG. 
 
 
Materials and Methods 
 
We recruited 10 consecutive patients admitted to the Liver Transplantation and Hepatobilitary 
Medicine Unit of the Royal Free Hospital who underwent a TIPS procedure. Exclusion 
criteria were refusal or inability to give consent. Informed consent was obtained, and the 
procedures followed in this study were in accordance with the regulations of the Local 
Research Ethics Committee of the Royal Free Hospital. The selected subjects were not taking 
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drugs known to affect coagulation parameters or platelet aggregation for at least 1 week 
before starting the study. 
Blood samples were taken for TEG before the procedure, at 1 hour after the procedure, at 6 
hours after the procedure and the morning after the procedure, with the possibility of taking 
further samples on a daily basis until any thromboelastographic changes had reverted to 
baseline. 
Blood samples were taken by a single peripheral venepuncture from the antecubital fossa 
using a 21 gauge butterfly needle and a light tourniquet to avoid stasis or platelet activation. 
Blood was collected into 3 mL polypropylene tubes containing 0.3 mL of 0.106M sodium 
citrate solution (Sarstedt Monovette, Leicester,UK; 9NC/10 ml tubes, nine parts venous blood 
to one part trisodium citrate) and gently inverted three times.  
TEG was performed using a computerized thromboelastograph (Haemoscope Corp., Skokie, 
Illinois, USA) as recommended by the manufacturer. The samples were stored at room 
temperature for 90 minutes as previously described by our group (286). After this time, 340 
µL of citrated blood were pipetted into the preheated cup containing 20 µL of 0.2M CaCl2 as 
activator. For each patient, a native (without heparinase) and a heparinase I-modified TEG 
was performed. 
The principal variables analysed by the TEG analyser are (Figure 4): the reaction time (r), 
which represents the rate of initial fibrin formation and is related to plasma clotting factors 
and circulating inhibitor activity; the clot formation time (k), which represents the time taken 
by the forming clot to reach a fixed degree of viscoelasticity and is related to the activity of 
the intrinsic clotting factors, fibrinogen and platelets; the alpha angle (α), which represents 
the rate of clot growth and is mainly a function of platelets, fibrinogen and plasma 
components residing on the platelet surface; and the maximum amplitude (ma), which is a 
reflection of the absolute strength of the fibrin clot and is a direct function of the maximum 
dynamic properties of fibrin and platelet number and function (269). 
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A heparin effect was defined as an improvement of at least 20 % of a TEG variable after 
addition of heparinase I. 
 
 
Results 
 
The 10 patients in our study (Table 11) were 6 male and 4 female. Mean age was 48.8 years 
(range 16 to 64). Aetiology of liver disease was alcohol in 6 patients, Budd Chiari disease in 
2, HCV related cirrhosis in 1 and cryptogenic cirrhosis in 1. The indication for TIPS 
placement was recurrent variceal bleeding in 4 patients, refractory ascites or hydrothorax in 4 
and Budd Chiari disease in 2. Patients were mostly in Child class B and C (5 and 4, 
respectively) and mean Child score was 8.8 (range 6 to 12). In all patients the TIPS was 
successfully placed. 
In 8 of 10 patients a heparin effect appeared on TEG after TIPS placement on the day of the 
procedure (7 patients) or day 1 post-procedure (1 patient) and disappeared within 24 to 48 
hours (Table 12). This heparin effect was present on at least 2 of 4 TEG variables in 7 out of 
the 8 patients, and in 3 of 4 TEG variables in 5 out of the 8 patients. When present after TIPS 
placement, the heparin effect was almost always detected by k time (7 of 8 patients) or alpha 
angle (7 of 8 patients), while no heparin effect could be detected with the maximum 
amplitude (ma). 
In only 2 of 10 patients (both with alcohol related cirrhosis, the indication for TIPS placement 
being refractory ascites in one and recurrent variceal bleeding in the other) was there a 
heparin effect before TIPS placement, and this was present in only 1 and 2 of the 4 TEG 
variables. One of these patients (Patient 4) never developed a heparin effect after TIPS 
placement, while the other patient (Patient 8) went on to develop a heparin effect after TIPS 
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placement in 2 TEG variables different from the single TEG variable where a heparin effect 
occurred before the procedure. 
In only 1 patient (Patient 1) no heparin effect could be detected either before or after the TIPS 
placement. 
 
 
Discussion 
 
Our study has shown the presence of a transient heparin effect in blood after the placement of 
a transjugular intrahepatic portosystemic shunt (TIPS) in the great majority of patients who 
underwent this procedure for a different number of indications. 
We have previously described the importance of bacterial infection in complicating cirrhosis 
and portal hypertension (298) and formulated the hypothesis that its presence may trigger 
variceal bleeding (59). 
We reported that 20 cirrhotic patients who had bled from varices, and then suffered early 
rebleeding, had a worse TEG trace on the day before rebleeding as compared to those who did 
not rebleed (144). TEG parameters have also been found to worsen in 84 decompensated 
cirrhotic patients in the presence of bacterial infection (145). A recent study found heparin 
activity in blood by using heparinase I-modified TEG in 28 of 30 patients with bacterial 
infection, but not in non-infected patients, and this effect disappeared after resolution of 
infection (23). This heparin effect was subsequently found to be associated with anti-Xa 
concentrations in many, although not all patients, suggesting that the heparin effect is due to 
an endogenous low molecular weight heparin (297). Moreover, a heparin effect was reported 
immediately after acute variceal bleeding in cirrhotics and thus could contribute to failure to 
control acute bleeding and early rebleeding (300). In a single study plasma heparan sulphate 
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concentrations were significantly raised in patients with recent variceal bleeding as compared 
to those without bleeding or non cirrhotic patients (146).  
Endotoxin or cytokines could release heparinoids from endothelium in a dose-dependent 
manner (23), and mast cell activation due to bacterial infection could also release heparin. 
There is statistically significant gradient of endotoxin concentrations between portal and 
peripheral blood (33), highlighting the role of the bowel as the source of endotoxin. Recently, 
bacterial translocation has been described as a common albeit transient event in patients with 
cirrhosis and ascites (71;301). 
In a pilot study we had attempted to perform TEG on portal blood sampled directly from the 
portal vein during the TIPS procedure, comparing it with venous blood drawn at the same 
time from a peripheral vein. Unfortunately almost every sample of portal blood taken in this 
manner clotted almost immediately, probably through activation of the coagulation cascade 
by the catheter used for accessing the portal vein. Thus we have been limited to assaying 
systemic blood. 
We did observe the presence of a heparin effect on systemic venous blood shortly after the 
creation of a significant shunt leading portal venous blood in the systemic circulation (and 
thus bypassing the hepatic filter) with a method known to be very sensitive for detection of 
heparin-like substances (302) such as TEG. Clearly the origin of the heparinoid effect could 
be from the splanchnic vasculature or due to liver trauma. In fact, we cannot entirely exclude 
that the presence of a heparin effect after TIPS placement might only be due to the amount of 
hepatic tissue damage during the TIPS procedure, with the subsequent release of hepainoid 
substances into the venous system. This would explain the transient nature of the heparin 
effect. However, the fact that not all patients presented the heparin effect despite the 
sensitivity of our method for heparinoid substances makes this hypothesis, in our view, less 
likely. 
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The presence of a heparin effect only after the TIPS procedure in the majority of patients 
suggests in our view a higher concentration of heparinoids in the portal venous system. The 
reason for two patients having a heparin effect before TIPS placement is not clear. It is 
certainly possible that these patients had a subclinical bacterial infection, which was 
subsequently treated (with disappearance of the heparin effect) by the prophylactic antibiotics 
administered to all patients undergoing TIPS placement. Also, it is not quite clear why both 
patients with Budd Chiari syndrome had a heparin effect after TIPS placement, as the 
presence of endogenous heparinoids has to our knowledge not yet been reported in these 
patients. However, the presence of portal hypertension in these patients might explain the 
same events of bacterial translocation and release of heparinoid substances as in the cirrhotic 
patients. The transient nature of the heparin effect after TIPS placement is also not entirely 
clear. It is possible that the endogenous heparinoid substances suddenly released into the 
systemic venous system after the procedure subsequently get diluted in the systemic venous 
system, and that heparinase I-modified TEG is not sensitive enough to detect the constant 
ongoing release after the procedure. 
In conclusion, our study reports the appearance of a transient heparin effect in systemic 
venous blood after TIPS in patients with cirrhosis or Budd Chiari syndrome, suggesting the 
presence of heparinoid substances in the portal venous system in these patients. Further 
research is warranted on the role of bacterial translocation as a fundamental factor in the 
occurrence of complications in patients with liver disease. 
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STUDIES ON BACTERIAL TRANSLOCATION AND INTESTINAL 
FUNCTION 
 61
 INTESTINAL FUNCTION AND PRESENCE OF BACTERIAL DNA IN SERUM AND 
ASCITES IN PATIENTS WITH CIRRHOSIS 
 
 
 
Introduction 
 
Bacterial infections are common in cirrhotic patients (3) and seem to play an important role in 
the development of the complications of cirrhosis (298), in particular with regards to variceal 
haemorrhage (21;23) and renal dysfunction (118;126).  
Bacterial translocation seems to be the initial step preceding the occurrence of overt bacterial 
infection in the cirrhotic patient (298). Bacterial translocation has been defined as the passage 
of microbes or microbial products into the mesenteric lymph nodes (50); for obvious reasons 
this is difficult to study in the human subject. However, the presence of bacterial DNA 
(detected by PCR) in biological fluids such as blood and ascites has recently been reported to 
correlate well with the presence of bacterial translocation in rats (303). 
Using this as a surrogate marker of bacterial translocation, Frances and coworkers reported in 
a recent study the presence of bacterial DNA in serum and ascites in 10 out of 17 patients 
with advanced cirrhosis without signs of infection from a minimum of 24 to a maximum of 72 
hours (71). 
On the other hand, it is also well known that patients with cirrhosis have an impairment of 
their intestinal function, involving increased permeability (47;304), reduced motility (45) and 
bacterial overgrowth (37;38). 
Our aim was to search for bacterial DNA in a range of cirrhotic patients both with and without 
ascites, and to study its correlation with any abnormality of intestinal motility or permeability 
and the presence of bacterial overgrowth. 
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Materials and Methods 
 
Patients 
We recruited 8 consecutive patients with cirrhosis. Cirrhosis was diagnosed by histology or 
by clinical, laboratory and/or ultrasonographic findings. Exclusion criteria were age of less 
than 18 years, presence of the systemic inflammatory response syndrome (SIRS)(305) or 
overt infection, upper gastrointestinal bleeding or intake of antibiotics (either systemic or 
luminal) within the preceding two weeks, history of intestinal disorders including major 
abdominal surgery, conditions impairing small bowel motility (such as diabetes mellitus or 
scleroderma), intake of lactulose, beta blockers, prokinetics or any other drug with an effect 
on small bowel motility, presence of hepatocellular carcinoma or portal vein thrombosis, 
acute alcoholic hepatitis, pregnancy and refusal of consent. The Ethics committee of our 
hospital approved the study protocol, and all patients provided informed consent. 
Blood and ascites samples were obtained by a single operator in aseptic conditions. On the 
day of recruitment blood was obtained for blood cultures (both aerobic and anaerobic, 10 mL 
each) and detection of bacterial DNA (in serum-gel bottles, 12 mL, Venosafe, Terumo, 
Leuven, Belgium), and ascites (if present) was obtained for culture in blood culture bottles 
(both aerobic and anaerobic, 10 mL each), standard neutral specimen bottles (20 mL) and 
detection of bacterial DNA (in serum-gel bottles, 12 mL, Venosafe, Terumo, Leuven, 
Belgium). On the following three days, blood was obtained in the morning for culture and 
bacterial DNA detection at 8 o’clock in the morning and for bacterial DNA detection at 2 
o’clock in the afternoon. 
 
Cultures 
Ascitic fluid (AF) sampled from patients were examined for the presence of bacteria using 
standard culture-based methods including the enrichment of the sample by inoculation in 
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blood culture bottles and incubation at 35°C for eight days. Moreover, samples of blood of 
each patient, taken twice each day for 4 days, were examined using the standard culture 
method.  
 
 
DNA extraction and purification 
Samples of 0.5 ml AF were treated with 0.5 mg/ml  proteinase K for 60 min to eliminate 
excess of proteins and were subsequently centrifuged at 1000 rpm for 5 min to eliminate red 
blood and other cells. Bacterial cells present in supernatants and in blood samples from the 
patients were broken in order to extract the DNA which was then purified using the kit 
Extragen (Nanogen) which has been shown to be very efficient in recovering nucleic acids 
from gram-negative and gram-positive species. For each sample, two internal controls 
consisted of 0.5 ml ascitic fluid added with 104 E. faecalis or E. coli cells were used. An AF 
sample demonstrated negative to the culture method and to DNA detection by PCR was also 
included as a negative control. Purified DNA was suspended in TE buffer and used for the 
PCR reaction. 
 
Polymerase chain reaction and visualization of amplification  products 
The nucleotide sequences and the properties of the primers designed to detect the different 
groups or species of bacteria are listed in Table 13. The PCR reaction was performed on a 
Thermal Cycler (Perkin-Elmer, USA). Final concentrations of the different components in the 
PCR reaction were: 10 mM Tris-HCl pH 8.8, 50 mM KCl, 1.5 mM MgCl2, 200 µM of each 
deoxynucleotide triphosphate, 100 pmol of each of the two primers of the pairs listed in Table 
13 and 2 U Taq DNA polymerase (Boehringer Mannheim).  PCR was performed twice on 
each sample in two separate experiments and also in a positive (E.coli + E. faecalis  purified 
DNA) and a negative (water instead of DNA) control, with 30 cycles consisting of 30-sec 
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denaturation at 94°C, 30-sec annealing at the adequate temperature and a 30-sec extension 
period at 72°C. A sample of 10 AL of the PCR product was resolved by 1% agarose gel 
electrophoresis at 100 V for 30 min in 0.5-Tris-borate-EDTA (pH 8.0) buffer containing 
ethidium bromide, and the images were visualized and photographed.  
 
PCR specificity and sensitivity test 
The specificity of each pair of primer was checked using DNA obtained from suspension of 
different bacterial groups or species cultures (see Table 13). The sensitivity of the method was 
evaluated by inoculating ascitic fluid with bacterial suspensions (106 to 10 cells) prepared 
from E. coli and E. faecalis cultures and extracting the DNA from 500 µl of each of the 
suspensions. 
 
Lactulose breath test (LBT)  
All patients underwent LBT to evaluate intestinal transit time and to detect small intestine 
bacterial overgrowth (SIBO).  
To minimize basal hydrogen (H2) excretion, subjects were asked to have a carbohydrate-
restricted dinner on the day before the test and to fast for at least 12 hours. Smoking and 
physical exercise were not allowed starting from 2 hours before testing. Before testing, 
patients had an antibacterial mouthwash with 20 mL of chlorhexidine 0.05%.  
End-alveolar breath samples were collected immediately before lactulose ingestion. 
Subsequently, a dose of 10 g of lactulose in 200 mL of water was administered and samples 
were taken every 15 minutes for 3 hours. From these bags, breath samples were aspirated into 
a 20 mL plastic syringe. Samples were evaluated for H2 using a gas chromatograph (Quintron 
microlyzer, Milwaukee, WI, USA). Results were expressed as parts per million (p.p.m.). 
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Orocaecal transit time was considered normal if a peak was observed within 90 minutes after 
the lactulose oral load. The peak was calculated as an increment of at least 20 ppm above the 
basal hydrogen value. 
A test positive for SIBO required an elevated breath hydrogen concentration within 90 min 
and two distinct peaks, the first being within 90 minutes. 
 
 
Intestinal permeability 
The intestinal permeability test was performed after the patients had been fasting overnight 
and emptied their bladder in the early morning before starting the test. A urine sample was 
collected before drinking 100 mL of a solution containing 10 g of lactulose and 5 g of  
mannitol dissolved in water. Urine was collected for the next five hours. Patients were asked 
to remain fasting for one hour after the start of the test and were then allowed to drink water 
for the remainder of the 5 hours. 
Total urine volume was measured and samples were centrifuged and kept at -20°C. 20 µL of 
the sample was analized using high performance liquid chromatography (HPLC; Agilent 
1200, Agilent Technologies, Santa Clara, CA, USA) to determine the concentration of urinary 
lactulose and mannitol. 
Intestinal permeability was expressed as the excretion ratio (R) of percentage of lactulose 
excreted in the urine (%L) to percentage of mannitol excreted in the urine (%M) 
(R=%L/%M). 
We used a sample of 14 healthy volunteers to determine normal values of intestinal 
permeability using our system. The mean±S.D. of %L was 0.25±0.10, the mean±D.S. of %M 
was 14.99±3.59 and the mean±S.D. of  the excretion ratio (R) was 0.02±0.005. 
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Results 
 
Of the 8 patients we recruited, one was excluded from the study after day 1 as he became 
encephalopathic and had to be treated with antibiotics. Thus data was available on 7 patients, 
6 males and a female. The mean age was 57.7 years (range 42 to 78 years, aetiology was 
alcohol in 3, HCV in 2, HBV and alcohol together with HCV in one patient each. Child-Pugh 
class was A in 4 patients and B in 3, and mean Child-Pugh score was 6.7 (range 5 to 9); 
ascites was present in 4 patients, oesophageal varices in 6 and encephalopathy in none (Table 
14). Baseline laboratory and clinical parameters are shown in Table 15. The main findings are 
summarised in Table 16. 
  
Intestinal transit time, permeability and bacterial overgrowth 
The median intestinal transit time was 135 minutes. Six of the 7 patients had a delayed 
intestinal transit time and one patient presented a physiologic H2 peak after 60 minutes. Two 
of the six patients without a peak within 90 minutes had no significant H2 rise even at the end 
of the test (180 minutes). One patient had a LBT positive for SIBO. 
Intestinal permeability was increased in all patients as compared to healthy controls, with the 
excretion ratio ranging from 0.027 to 0.072 (mean±S.D. 0.05±0.01) as compared to normal 
values of 0.02±0.005 in the healthy volunteers (Table 17). 
 
Bacterial DNA 
Of all the samples analysed, only one sample of ascitic fluid and 8 samples of serum (all taken 
from the same patient) were PCR positive using universal primers. In all the other samples 
from the remaining patients, PCR using universal primers was negative. The samples that 
were PCR positive for universal primers were also positives to PCR with EntB primers 
specific for Enterobacteriaceae (Figure 8). The same samples analyzed by PCR with primers 
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eco and pbp5 resulted negative, indicating that in these samples there was no DNA from 
Escherichia coli or Enterococcus faecalis. 
 
 
Discussion 
 
The importance of the sequence of events starting from bacterial translocation and leading up 
to bacterial infection in the cirrhotic patient has been increasingly recognised in recent years 
(59;298). Bacterial translocation and different intestinal dysfunctions (such as altered motility, 
permeability and bacterial overgrowth) in the setting of chronic liver disease have been 
described in several studies. 
Altered small bowel motility leading to delayed intestinal transit has been shown in cirrhosis 
(43;45). with a direct relationship between these changes and the severity of liver disease 
(45). A significantly increased frequency of cluster of contractions and an increased duration 
of phase II of the migrating motor complex were seen in patients with liver cirrhosis (43;306); 
these changes have been reported to resolve after orthotopic liver transplantation (307). In 
patients with cirrhosis, bacterial overgrowth has been shown in one third of alcoholic 
cirrhotics, especially those with ascites and severe liver dysfunction (37). According to Perez-
Paramo et al, a coordinated bowel motor function might be the most important mechanism for 
preventing bacterial overgrowth (36). 
Intestinal permeability is impaired by portal hypertension, particularly with severe liver 
disease (47), especially if there is ongoing alcohol intake (48;49;304). Gastrointestinal 
mucosal abnormalities (leading to increased permeability) due to portal hypertension (40) can 
be caused by the overproduction of nitric oxide (NO), which leads to disruption of the 
integrity of the intestinal epithelium (50). Also, the oedema of the splanchnic tissues in portal 
hypertension may affect the permeability of the gut (46). 
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Bacterial translocation occurs with an incidence ranging from 37 to 83 % in animal cirrhotic 
models (50). In human cirrhosis, the incidence of bacterial translocation is also related to the 
degree of portal hypertension and liver dysfunction, being reported in approximately 30 – 40 
% of cirrhotics with ascites (36;63;66) and more frequently in Child C than in Child A and B 
cirrhosis (66). In a recent study, 7 of 17 advanced cirrhotics with culture-negative, 
nonneutrocytic ascites had the simultaneous presence of bacterial DNA (a surrogate marker of 
bacterial translocation (303)) in blood and ascitic fluid at admission to hospital, which 
persisted in blood for 24-72 hours (71). Furthermore, nucleotide sequencing demonstrated that 
bacteria detected in the first sample were identical to those detected later, proving that 
bacterial translocation is a single-species, dynamic process (71). 
In the 7 patients reported in this study, intestinal motility and permeability were impaired in 
virtually all patients, both with ascites and without. The presence of bacterial DNA in the 
ascitic fluid and serum, however, was found in only a single patient with ascites (14 %), as 
compared to 7 out 17 ascitic patients (41 %) reported by Frances and colleagues (71). 
Bacterial overgrowth was also present in only one patient of our group. Not surprisingly, the 
only patient with presence of bacterial DNA was also the one with the hightest intestinal 
permeability. 
The main difference between our group of patients and the group reported by Frances and 
colleagues (71) is the severity of liver disease. While only four of our seven patients had 
ascites, this was present in all of their patients; moreover, while none of our patient was in 
Child-Pugh class C, none of their patients was in Child-Pugh class A. However, portal 
hypertension was present in almost all of our patients as confirmed by the presence of 
oesophageal varices. 
In addition to the findings of Frances and colleagues (71), we report for the first time the 
relationship between the presence of bacterial DNA in biological fluids and alterations of 
intestinal dysfunction in the natural history of cirrhotic patients. Our findings suggest that 
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decreased intestinal motility and increased intestinal permeability are early events occurring 
even in patients with relatively preserved liver function, while both the presence of bacterial 
overgrowth and the appearance of bacterial DNA in serum or ascitic fluid seem to be related 
to increasing severity of liver disease, as already suggested by other authors (37;66). 
Altered small bowel motility, bacterial overgrowth in the small intestine, and increased 
intestinal permeability all lead to increased endotoxaemia, increased bacterial translocation 
and ultimately the risk of bacterial infection in cirrhotics. In cirrhotic rats with ascites, 
bacterial overgrowth is promoted by intestinal hypomotility, and bacterial translocation only 
occurs in presence of overgrowth and severe disruption of the gut barrier (36). Bacterial 
translocation also increases in cirrhotic rats after the development of ascites (63). 
The limitations of our study are the relatively small sample and the fact that we only 
monitored for the presence of bacterial DNA in biological fluids in a limited time frame of 
four days, thus potential missing episodes of bacterial translocation (since it is known that this 
is a transient occurrence in the cirrhotic patient (71)). However, the timeframe chosen was 
identical to the one used in the previous study (71). It is also unexpected that the only patient 
with bacterial overgrowth did not have ascites and had a good liver function with a Child-
Pugh score of 5. Another possible limitation is that two of the patients with no physiological 
H2 peak within 90 minutes had no peak even at the end of the test at 180 minutes. This is most 
likely to be explained by a severely delayed intestinal transit, however a lack of colonization 
by H2 producing bacteria cannot be excluded. Also, while lactulose breath testing is an 
established method for the assessment of intestinal transit time, its accuracy regarding the 
detection of small bowel bacterial overgrowth (SIBO) is less than optimal, with a sensitivity 
of 68 % and a specificity of 44 % (308). The gold standard for assessing SIBO is culture of 
small bowel aspirate (308), which however is an invasive method; while xylose breath test 
seems to be performing better with regard to other non invasive methods. However, we 
decided to use the lactulose breath test as it allowed us to assess intestinal transit time and 
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SIBO with a single technique, thus avoiding the need for two different breath tests which 
might have prolonged the length of hospitalization. 
Our findings are of importance as they contribute a further essential piece of information to 
the understanding of the natural history of cirrhosis and portal hypertension, in particular with 
the occurrence of bacterial translocation and infection leading to further complications, and 
also provide the scientific rationale for the development of new therapeutic approaches. 
The circumstantial evidence associating bacterial translocation and infection with intestinal 
dysfunction in this setting has already been reviewed (298). An increase in permeability was 
correlated with the occurrence of septic complications in 80 patients with mainly alcoholic 
cirrhosis (47). A history of spontaneous bacterial peritonitis (SBP) (a haematogeneous 
infection localising in ascitic fluid, the source most likely being bacteria translocating from 
the gut) is associated with more severe intestinal dysmotility and more frequent bacterial 
overgrowth (38). Bacterial overgrowth leads to bacterial translocation and together with 
increased intestinal permeability leads to an increased risk of SBP and worsening of hepatic 
encephalopathy (55). Cisapride and antibiotics (such as norfloxacin and neomycin) improve 
both small intestine dysmotility and bacterial overgrowth in cirrhosis (56). Interestingly, 
propranolol, which lowers portal pressure, reduced the risk of post surgical infections from 42 
% to 15 % in a cohort of 73 cirrhotics (57). This protection may be due to increasing bowel 
motility by its sympatholytic action, indirectly decreasing microbial translocation. A recent 
retrospective study of 139 patients suggested that propranolol also may prevent SBP (58;309). 
Selective intestinal decontamination with antibiotics reduces bacterial translocation (66) and 
decreases the risk of infections, especially those due to Gram negative bacteria (78;79). 
Moreover, the addition of cisapride (a prokinetic agent) to norfloxacin has been reported to 
further decrease the incidence of SBP in cirrhotic patients with ascites (310). This again 
supports the role of intestinal bacteria as a major infective source in cirrhotics and may 
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explain why prophylactic antibiotics both orally and intravenously are so effective in reducing 
infections during variceal bleeding (80). 
In conclusion, our study shows the presence of impaired intestinal motility and permeability 
in a cohort of cirrhotic patients (both with ascites and without) with a relatively preserved 
synthetic liver function but with presence of portal hypertension, while both the occurrence of 
bacterial overgrowth and bacterial translocation as defined by the detection of bacterial DNA 
in biological fluids only occurred in one patient each. We suggest that reduced intestinal 
motility and increased permeability (which may at least in part be correlated to the presence 
of portal hypertension) precede the occurrence of bacterial overgrowth and bacterial 
translocation in cirrhotic patients. Further studies are needed to explore the natural history of 
intestinal dysfunction and bacterial translocation in cirrhosis and to study possible therapeutic 
interventions such as the use of probiotics, selective intestinal decontamination, prokinetic 
agents and non selective beta-blockers in this setting. 
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METHODOLOGICAL STUDIES IN PORTAL HYPERTENSION 
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ASSESSMENT OF THE AGREEMENT BETWEEN WEDGE HEPATIC VEIN PRESSURE 
AND PORTAL VEIN PRESSURE IN CIRRHOTIC PATIENTS 
 
 
 
Introduction 
 
The measurement of the portal pressure gradient provides prognostic information in the 
management of patients with cirrhosis (311;312) and we believe it should be more widely 
used given that it has independent prognostic significance over and above scores of the 
severity of liver disease (311). For many years, measuring hepatic venous pressures, both the 
free pressure (FHVP) and the wedged pressure (WHVP), either with a wedge catheter or a 
balloon catheter (313), has been the standard approach for estimating portal venous pressure 
(PVP) (311;314-316). 
 
Several studies have compared WHVP with portal pressure in cirrhotic patients but with 
relatively small cohorts and using different techniques for assessing portal pressure (Table 
18). Some of them found good correlation between the two measurements, especially in 
patients with alcoholic cirrhosis (316-322) and HBV cirrhosis (323); other studies reported 
less good correlations between the two techniques, especially in patients with non-alcoholic 
cirrhosis (317;319;324-326). In HCV cirrhotic patients in particular, the data is conflicting 
(318;324). 
 
Recently, the precision in measuring WHVP per se has been questioned (327). In this study, 
61 % of the hepatic venous pressure gradient (HVPG) measurements in two separate hepatic 
veins differed by as much as 4-34 mm Hg. If confirmed, this finding would raise serious 
doubts about the validity of WHVP measurement as a reliable way of estimating PVP. 
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Thus, our aim was to evaluate the agreement between HVPG and portal pressure gradient 
(PPG) by systematically reassessing all the published data comparing these two measurement 
techniques. In particular, as the use of correlation for comparing two measurement techniques 
has been criticised as inappropriate (since it only describes a linear correlation between 
variables, but not necessarily an agreement), we decided to also apply an alternative approach 
which has been advocated for this purpose (291). 
 
 
Materials and methods 
 
We conducted a full Medline search in all languages for studies comparing wedge hepatic 
venous pressure with portal pressure, using the keywords “cirrhosis”, “wedge hepatic venous 
pressure”, “WHVP”, “hepatic venous pressure gradient”, “HVPG”, “portal pressure” both 
alone and in combination between each other. We also searched the bibliographies of all 
relevant papers. In this way we identified 17 studies, which had individual patient 
measurements, comparing WHVP with PVP (316-326;328-333). We could only include 11 of 
these in our study; in 5 of them the measurements were reported as individual numerical 
values (316;322;325;326;331), in the remaining 6 we were able to extract the values from the 
graphs (317;318;320;321;323;324). We excluded 6 studies from our evaluation, because in 2 
it was not possible to determine which measurements had been taken in patients with liver 
disease (332;333), in 1 because only pressure changes after vasoactive drug therapy were 
reported (330), in 1 because it was not possible to extract the data from the graph (319), in 1 
because the two different measurements were taken at a long time interval from each other 
(329) and lastly in 1 because it only considered patients with spontaneous portosystemic 
encephalopathy who were very likely to have a significant portosystemic shunt (328). 
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We pooled all the data from the published studies and recalculated the determination 
coefficient (r2) with linear regression determined by using GraphPad Prism version 4.00 for 
Windows (GraphPad Software, San Diego California USA, www.graphpad.com). The r2 gives 
the fraction of variability in one variable explained by the other variable, in this case the 
prediction of portal venous pressure by measuring WHVP and PPG by measuring HVPG. 
Thus the r2, as compared to the more commonly used r (regression coefficient), which was 
used in the individual articles correlating portal pressure to WHVP and HVPG, is the most 
appropriate expression of the correlation we wished to test. 
 
We evaluated agreement between the two measurements using the method described by Bland 
and Altman (291), i.e. by plotting the difference between the two measurements against their 
mean. As this method does not allow a quantification of the degree of agreement, we 
evaluated it by describing the absolute number and percentage of values outside 1.96 standard 
deviations (i.e. commonly referred to as 2 standard deviations). We considered less then 10 % 
of the values being outside 1.96 standard deviations as a good agreement. 
 
We also evaluated the difference between the two methods in relation to basal PVP in order to 
assess if there was an increasing error dependent on the degree of PVP. 
 
 
Results 
 
We identified a total of 320 comparative measurements of WHVP and PVP and 75 
comparative measurements of HVPG and PPG; 102 comparative measurements of WHVP 
and portal pressure were performed in patients with alcoholic liver disease and 88 in patients 
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with non-alcoholic liver disease. In the latter group 53 had hepatitis C virus (HCV) related 
liver disease (an additional 14 had both alcoholic liver disease and HCV related liver disease), 
other aetiologies included in this group were hepatitis B virus (HBV) related liver disease, 
primary biliary cirrhosis (PBC) and autoimmune hepatitis, as well as cryptogenic cirrhosis. A 
total of 194 measurements were performed with a wedge catheter and 113 with a balloon 
catheter. 
 
 
All patients 
 
Evaluating the 320 measurements comparing WHVP and PVP, WHVP was greater than PVP 
in 113 measurements and PVP was greater in 138 measurements. The range of difference 
between WHVP and PVP was from -22.1 to 10 mm Hg (mean±1.96 S.D. being -0.48±6.33 
mm Hg, median 0 mm Hg). We found a coefficient of determination (r2) of 0.87. From the 
graph (Figure 9A) it can be seen that 2 cases, both from the same author (325), are outliers. 
By excluding these two cases as outliers the r2 is 0.90 and the range of difference was from -
10.5 to 10 mm Hg. According to Bland and Altman plot (Figure 9B), there were no absolute 
systematic errors, no proportional errors and no variation depending on the magnitude of 
measurement. However, the range of -0.48±6.33 mm Hg is clinically important. 
If only the 101 measurements for which individual numerical values were available 
(predominantly earlier studies) are considered, the r2 is 0.68 (0.70 excluding the outliers) and 
according to Bland and Altman plot, there were no absolute systematic errors, no proportional 
errors and no variation depending on the magnitude of measurement, however, the range of -
1.36±7.31 mm Hg is clinically important. Considering only the 219 measurements for which 
values were extracted from graphs (predominantly later studies), the r2 was 0.91 and 
according to Bland and Altman plot, there were no absolute systematic errors, no proportional 
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errors and no variation depending on the magnitude of measurement, however, the range of -
0.08±5.66 mm Hg is clinically important. 
 
Evaluating the 75 measurements comparing HVPG and PPG (316;320;322;331), HVPG was 
greater than PPG in 21 measurements and PPG was greater in 23 measurements. The range of 
difference between WHVP and PVP was from -4 to 8.5 mm Hg (mean±1.96 S.D. being -
0.05±3.39 mm Hg, median 0 mm Hg).  The r2 was 0.90; according to Bland and Altman plot, 
there were no absolute systematic errors, no proportional errors and no variation depending on 
the magnitude of measurement. However, the range of 0.05±3.39 mm Hg is clinically 
important (Figure 9C and 1D). 
 
Alcoholic liver disease 
 
Evaluating the 102 measurements (317;318;320-322;326) comparing WHVP and PVP, 
WHVP was greater than PVP in 33 measurements and PVP was greater in 45 measurements. 
The range of difference between WHVP and PVP was from -8 to 9 mm Hg (mean±1.96 S.D. -
0.4±5.23 mm Hg, median 0 mm Hg).  There was a r2 of 0.93; according to Bland and Altman 
plot, there were no absolute systematic errors, no proportional errors but there was an 
increasing variation of at least one method depending on the magnitude of measurement. The 
range of -0.4±5.23 mm Hg is clinically important (Figure 10A and B). 
Amongst the 13 measurements (320;322) comparing HVPG and PPG the r2 is 0.84; 
considering the Bland and Altman plot, absolute systematic errors, proportional errors and 
variation depending on the magnitude of measurement were difficult to assess due to the 
small number of measurements. The range of -0.38±3.63 mm Hg is clinically important 
(Figure 10C and D). 
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Non-alcoholic liver disease 
 
Amongst the 88 measurements (317;318;321;323;324) comparing WHVP and PVP, WHVP 
was greater than PVP in 38 measurements and PVP was greater in 41 measurements. The 
range of difference between WHVP and PVP was from -10.5 to 10 mm Hg (mean±1.96 S.D. -
0.39±6.45 mm Hg, median 0 mm Hg).  The r2 is 0.83; according to Bland and Altman plot, 
there were no absolute systematic errors, no proportional errors and no variation depending on 
the magnitude of measurement. However, the range of 0.39±6.45 mm Hg is clinically 
important (Figure 11A and B). 
In particular, in the 53 measurements (318;324) comparing WHVP and PVP in patients with 
HCV related liver disease, WHVP was greater than PVP in 23 measurements and PVP was 
greater in 22 measurements. The difference between WHVP and PVP ranged from -10.5 to 10 
mm Hg (mean±1.96 S.D. -0.08±7.39 mm Hg, median 0 mm Hg).  The r2 is 0.75; according to 
Bland and Altman plot, there were no absolute systematic errors, no proportional errors and 
no variation depending on the magnitude of measurement. However, the range of -0.08±7.39 
mm Hg is clinically important (Figure 11C and D). 
No measurements comparing HVPG and PPG were available in this subgroup. 
 
 
Wedge catheter measurement 
 
Evaluating the 194 measurements (316;317;320-322;326;331), WHVP was greater than PVP 
in 59 measurements and PVP was greater in 82 measurements. The range of difference 
between WHVP and PVP was from -9 to 8.5 mm Hg (mean±1.96 S.D. -0.55±4.78 mm Hg, 
median 0 mm Hg).  The r2 is 0.85; according to Bland and Altman plot, there were no 
absolute systematic errors, no proportional errors and no variation depending on the 
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magnitude of measurement. However, the range of -0.55±4.78 mm Hg is clinically important 
(Figure 12A and B).  
As all the measurements comparing HVPG and PPG were performed using a wedge 
cathether, the results are the same as reported for the whole series. 
 
Balloon catheter measurement 
 
Amongst the 113 measurements (318;323;324), WHVP was greater than PVP in 49 
measurements and PVP was greater in 41 measurements. The range of difference between 
WHVP and PVP was from -10.5 to 10 mm Hg (mean±1.96 S.D. -0.19±6.17 mm Hg, median 0 
mm Hg).  The r2 is 0.90; according to Bland and Altman plot, there were no absolute 
systematic errors, no proportional errors but there was an increasing variation of at least one 
method depending on the magnitude of measurement. However, the range of -0.19±6.17 mm 
Hg is clinically important (Figure 12C and D). 
 
Assessment of the variability between direct and indirect portal pressure measurement 
according to basal portal pressure 
 
The assessment of the absolute difference between the two types of measurement, in all 
measurements and in those performed with a balloon catheter, plotted against the basal PVP 
showed that the variability was constant for a range of PVP from 1 to 45 mm Hg (Figure 13 A 
and C). A similar distribution was seen for measurements performed with a wedge catheter 
and in separate subgroups of patients with and without alcoholic liver disease. 
The difference between the two measurements, as a change in percentage from WHVP 
measurement, plotted against the PVP, showed a tendentially greater change in percentage for 
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lower PVP pressures (<20 mm Hg) (Figure 13 B), but this was not observed when only the 
measurements performed with a balloon catheter were considered (Figure 13 D). 
 
 
Discussion 
 
Our reassessment of the data published to date on comparative measurements of wedged 
hepatic pressures and portal pressures clearly shows that WHVP correlates well with PVP in a 
cohort of patients with alcoholic liver disease, HBV and HCV related liver disease, PBC and 
autoimmune hepatitis, irrespective of the use of a wedge or a balloon catheter. However there 
was a trend to greater differences between the wedge technique and PVP at lower PVP 
pressures but this did not reach statistical significance. In particular, it is important to note that 
this also holds true for the main aetiologies of liver cirrhosis, alcoholic liver disease and HCV 
related liver disease, despite some claims to the opposite (324). Furthermore, we also 
confirmed that HVPG correlates significantly with PPG. 
These findings are of great importance, as measurement and monitoring of hepatic pressure 
measurements (HVPG and WHVP) are increasingly recommended in clinical trials and 
clinical practice regarding the pharmacological prevention of portal hypertension-related 
bleeding (334-336). Moreover, a higher HVPG measurement is known to be an independent 
factor associated with mortality in liver cirrhosis (311) and one study has linked 
pharmacological reduction in HVPG to a decreased long-term risk of complications related to 
portal hypertension, such as variceal bleeding, ascites, spontaneous bacterial peritonitis, 
hepatorenal syndrome and hepatic encephalopathy (312;337). A recent report also suggests 
that changes in HVPG could be considered as an adjunctive end point for the therapeutic 
evaluation of antiviral therapy in chronic hepatitis C, and HCV related cirrhosis (338). 
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Our findings do not confirm a recently reported high variability in HVPG measurements 
(327), as the correlation with PPG measurements was highly significant, across 8 different 
centres reporting data, given that direct portal pressure measurement has very little variability. 
The paper by Keiding et al (327) used a wedge catheter technique and did not compare 
WHVP with PVP. On the whole, WHVP measurement seems to slightly underestimate PVP, 
but the difference is small (mean -0.48 mm Hg). 
 
We also assessed the agreement between portal pressures and WHVP and HVPG with the 
method proposed by Bland and Altman (291). This is important since this method has been 
suggested to be more appropriate for assessing agreement between two methods of clinical 
measurements, as the use of correlation coefficients in this setting may be misleading. The 
Bland and Altman method showed a clinically significant range of differences, with 95 % of 
the differences lying between 3.39 mm Hg above or below the mean and 7.39 mm Hg above 
or below the mean. This variability is of importance, especially if such small variabilities as 
10 % or 20 % reductions from baseline are considered, as have been reported to be important 
in the setting of prophylaxis of variceal bleeding and complications of portal hypertension in 
general (339;340).  
 
One possible bias in our evaluation is that the number of measurements might have been too 
small thus leading to a larger standard deviation. However, even considering the total number 
of available measurements (i.e. 320) the range of differences is still clinically significant (6.33 
mm Hg above or below the mean). Another possible source of heterogeneity is that studies 
included were performed over a 44 year time span with consequent variation in equipment 
and technique of measuring pressure. However, the distinction between studies performed 
using the wedge technique (1955-1985) and those using the balloon technique (1989-1999) 
takes into account most of these differences.  
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Lastly, there is an issue of generalisability. All of these studies were performed in specialised 
centres, and thus these results may not be reproducible in a routine setting. However, 
recommendations for an accurate technique have been published recently(341) and should 
make accurate measurements achievable in every institution. 
 
This analysis, although confirmatory of other studies with regard to the correlation between 
WHVP and PVP and between HVPG and PPG, each with a small number of patients, 
questions the agreement between these variables and thus the use of WHVP and HVPG 
measurements as surrogate measurements of PVP and PPG. To our knowledge, this is the first 
time that an assessment of more than 300 comparative measurements has been performed. 
The suboptimal accuracy of WHVP and HVPG as indirect indices of portal pressure reported 
here, should be, we believe, a further stimulus to a more widespread study of these methods. 
It may well be that performed with a correct and repeatable technique (341), these techniques 
could result not only in good correlation, but also in acceptable agreement. This is especially 
important as the use of HVPG holds great promise for prognostic estimation (311;312), for 
researching the role of target reduction of portal pressure during pharmacological therapy of 
portal hypertension (334-336) and potentially as a surrogate marker of chronicity or fibrosis 
(338). 
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COMMENTS ON THE IMPORTANCE OF DIFFERENT 
PATHOPHYSIOLOGICAL MECHANISMS IN COMPLICATIONS OF 
PORTAL HYPERTENSION – THE EXAMPLE OF HAEMODYNAMIC NON 
RESPONDERS TO PHARMACOLOGICAL TREATMENT  
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HOW TO PREVENT VARICES FROM BLEEDING: SHADES OF GREY – THE CASE 
FOR NON-SELECTIVE BETA BLOCKERS 
 
 
 
Introduction (Black and white) 
 
The risk of bleeding from oesophagogastric varices is determined by the extent of portal 
hypertension, liver dysfunction and endoscopic findings (342). Portal hypertension is 
responsible for many of the complications of cirrhosis and warrants treatment in patients who 
have already suffered a variceal haemorrhage as well as those who have a risk of bleeding for 
the first time. This can be pharmacological by lowering portal pressure or local treatment of 
the varices by ligation at the site of bleeding. Recently some data suggests that reduction in 
portal pressure might also be beneficial for other outcomes, such as ascites, spontaneous 
bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy and overall survival 
(340;343). Whether a therapeutic benefit can occur without improvement of liver function, 
providing there is a reduction in portal pressure, has recently been discussed (344;345). 
However, this has only been assessed in a subgroup of 31 patients (344) so further data is 
clearly needed. The pharmacological treatment most commonly used is non-selective beta 
blockers (propranolol, nadolol or timolol) either as monotherapy or in association with 
nitrates. The presence or absence of a decrease in the hepato-venous pressure gradient 
(HVPG), a surrogate marker of portal pressure(346;347), either by a certain degree (20 % or 
more) or below an absolute value (12 mm Hg) have been advocated as a prognostic tool in 
order to predict the therapeutic effect – the prevention of bleeding and rebleeding (343;348). 
However the applicability of routine remeasurement of HVPG as well and the generalisability 
of the published data have been questioned ((339;349-354)). 
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Patients treated with portal pressure lowering drugs can be divided into “white” 
(haemodynamic responders) or “black” (haemodynamic non-responders). Thus those patients 
achieving an HVPG reduction of >20 % from baseline or below 12 mm Hg, are considered to 
be at far less risk of  rebleeding (“white”), whereas the others are believed to be at continued 
risk of rebleeding which is greater than the responders’ (“black”). These latter patients are 
then to be considered for alternative therapies such as ligation or more aggressive treatments 
such as TIPS to evade this fate. However although ligation is often recommended, current 
data suggests rebleeding still occurs even if patients are switched to endoscopic treatment 
(355;356). Indeed, the relationship between the absence of a good response with non-selective 
beta blockers and bleeding is not a close correlation and prediction of bleeding in an 
individual patient is not sufficiently good for routine clinical practice. This consideration has 
often been taken as a reason to choose ligation of varices as the choice of first therapy for 
prevention of rebleeding. 
 
The aim of this paper is to review the evidence for dividing patients into “black” and “white” 
(a division which we consider to be too simplicistic) and to make a case for propranolol to be 
used for primary and secondary prevention of bleeding, providing there are no 
contraindications or intolerance, in all patients. 
 
 
Haemodynamic response and efficacy of drug treatment – clinical evidence 
 
Non-selective beta blockers, with or without nitrates, are effective for preventing the first 
variceal bleeding episode in patients with moderate or large varices, and for preventing 
variceal rebleeding (342;357;358). However, the protective effect of non-selective beta 
blockers may not only be due to reduction in portal pressure, but may also be due to a  
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reduction of bacterial translocation (through an effect on intestinal motility, permeability and 
bacterial overgrowth(359)) and a reduction in bacterial infections(309;359), and through this a 
reduction in the risk of bleeding. 
Several studies have assessed the haemodynamic response with respect to the risk of variceal 
haemorrhage, mostly in the setting of secondary prophylaxis (360-364), but also in primary 
prophylaxis (340;365;366) or in cohorts with patients undergoing both primary and secondary 
prophylaxis (356;367). 
 
For prevention of rebleeding, the association with target reduction of portal pressure is clear 
cut in those in whom pressure was remeasured between 1 and 3 months after starting therapy. 
However, the fact that hepatic venous pressure measurements were not measured at baseline 
or repeated in all patients, especially in those patients who rebled before remeasurement, 
further complicates the interpretation of the data (350;351). 
 
What can be determined from the current data is that not all haemodynamic responders will 
stay free of bleeding/rebleeding unless HVPG is below 12 mm Hg (but only a median of 14 % 
achieve this response) (351) and conversely, not all non-responders will eventually bleed or 
rebleed. 
 
Considering the 5 studies assessing haemodynamic response for the secondary prophylaxis of 
variceal bleeding, a total of 138 out of 211 patients on drug treatment who had their 
haemodynamic response assessed did not rebleed, of which 57 (41.3 %) were non responders 
(Table 19). Even excluding the study by McCormick and coworkers(361), which has been 
criticised for assessing haemodynamic response only at 5 months (i.e. very late), 45 out of 
110 patients who did not rebleed (40.9 %) were non responders. Moreover, it is often not 
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emphasized that the percentage of patients not rebleeding was consistently higher than the 
haemodynamic response rate in all trials (median, 64 % vs 51 %). 
 
With regard to the variability in bleeding rates in relation to pressure response, an interesting 
parallel can be made by evaluating studies using nitrates. The addition of isosorbide 
mononitrate (ISMN) has been shown to reduce HVPG, even in patients who have no 
haemodynamic response to propranolol (368;369). However, this effect does not always 
translate into a significantly increased clinical efficacy. ISMN as monotherapy does not 
reduce the incidence of first variceal bleeding (370), and in one (out of two) randomized 
controlled trials for primary prophylaxis, its addition to propranolol made no improvement to 
the incidence of variceal haemorrhage (371). The randomized trials evaluating combined 
treatment versus non-selective beta blockers alone for prevention of rebleeding showed 
trends, but not clear cut significant benefit for combination treatment (372;373) 
 
In the two randomized controlled studies (from the same centre) of pharmacological versus 
endoscopic prophylaxis for variceal rebleeding that also assessed haemodynamic response, 
non-responders to non selective beta-blockers had the same incidence of rebleeding as 
patients undergoing sclerotherapy (55 % vs 53 %) and a slightly higher incidence compared to 
those undergoing endoscopic banding ligation (67 % vs 49 %) (363;364). 
 
Overall, 22 to 67 % (median, 47 %) of non-responders rebleed (351), which is lower and at 
least not worse than historical controls with a 63 % bleeding rate at 2 years without treatment 
(348). In trials of primary prophylaxis, the bleeding rate in non-responders was 37 % during 
follow-up for up to 5 years (excluding patients with small varices without red signs) 24, while 
a more recent study3 (recruiting all patients with varices) had a bleeding rate of 30 % in the 
non-responder group during a follow-up period of up to 8 years. This compares favourably to 
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a historical risk of 26.5 % at one year without treatment (and thus comprising both potential 
responders and non-responders) 32. Indeed the positive predictive value of haemodynamic 
non-response for variceal rebleeding is as low as 52.1 % when pooling the data from the trials 
(Table 20). 
In contrast to the above results, a non randomised study proposing “à la carte” treatment for 
portal hypertension (356), aimed at the target of achieving a haemodynamic response of 
lowering HVPG below 12 mm Hg or by at least 20 %. However, those patients not achieving 
these targets with propranolol alone or in combination to ISMN had their beta blockers 
discontinued and were switched to endoscopic banding ligation and had a very high 
rebleeding rate of 87 % - more than twice the median of the other studies. This raises doubts 
as to whether this cohort is representative of non-responders, or whether indeed those patients 
had been experiencing a protective effect from the drug treatment before this was suspended, 
in spite of not achieving a haemodynamic response. It is known that patients under non-
selective beta blockers lose all benefits from drug treatment and return to their prior bleeding 
risk once this is stopped (374). In addition, if the results from this study(356) were 
representative of non-responders, it would suggest that even banding ligation is not effective 
for non-responders to beta blockers. A recent uncontrolled study showed a low rebleeding rate 
in “partial responders” (HVPG reduction of ≥10 % and <20 %) with the combination of 
pharmacological treatment and banding ligation(375), suggesting that a beneficial effect may 
also be observed with moderate decreases in HVPG. 
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Alternative pathopysiological mechanisms for the action of non selective beta blockers 
(Table 21) 
 
 
1) Alternative haemodynamic mechanisms 
 
The protective effect of propranolol (376) in preventing variceal bleeding is thought to be 
mediated in several ways. The major effect is by a reduction of portal inflow (377;378) 
resulting from a decrease of cardiac output and from splanchnic vasoconstriction (379-381). 
Another haemodynamic mechanism, often overlooked, is an increase in porto-collateral 
resistances reducing blood flow to varices. Indeed, propranolol decreases azygos blood flow 
(382-386) (an index of collateral blood flow) and variceal pressure (367;383;387). Some 
authors consider the reduction of collateral blood flow and variceal pressure as the principal 
mechanism by which propranolol reduces bleeding risk in cirrhotic patients (382;383). 
Finally, propranolol also causes a decrease in total effective vascular compliance (388;389), 
so that HVPG is further reduced because free hepatic vein pressure (FHVP) is increased. 
Propranolol therapy also increases intrahepatic vascular resistance, thereby potentially 
offsetting, at least partially, its beneficial effect on portal pressure (390;391). For this reason, 
combination therapy with vasodilators, such as nitrates or prazosin, or the use of carvedilol (a 
non selective beta-blocker with intrinsic alphalytic activity) have been advocated (392;393). 
All of these drugs have been shown to increase the haemodynamic response rate as assessed 
by HVPG. Yet, by looking closely at the other haemodynamic variables in these studies, some 
differences become evident. 
Propranolol reduces azygos venous blood flow by a greater extent (34-38 %) than either 
cardiac output (23-24 %), HVPG (11-14 %) or hepatic blood flow (13 %) (382;394). As 
hepatic blood flow is the sum of both portal venous and hepatic arterial blood flow, the fact 
 90
that propranolol reduces hepatic blood flow to a lesser extent than azygos blood flow may be 
due to a relative increase in hepatic artery blood flow after beta-blockade, as seen in an 
experimental portal hypertension model in rats (395), despite an increase in hepatic resistance 
(390). Propranolol decreases azygos blood flow (382;384;386;394;396-398) through an effect 
of beta-blockade (384), and does so even in patients without a haemodynamic response as 
assessed by HVPG (383;386). 
On the other hand, the addition of ISMN to propranolol, whilst further decreasing HVPG, 
results in a non significant increase (394) of collateral blood flow (as estimated by azygos 
blood flow). Administration of ISMN alone leads to no change in azygos blood flow (369) or 
to a slight decrease by 11 % (368). A study comparing propranolol with the combination of 
propranolol and ISMN found no significantly greater reduction of flow in the combination 
group as compared to propranolol alone (398). Carvedilol reduces azygos blood flow less than 
propranolol (by 15-20 % for carvedilol vs 23-27 % for propranolol) despite a greater 
reduction in HVPG (393;399). As regards prazosin we were not able to find any published 
data on its effect on azygos blood flow. 
Variceal pressure is correlated with azygos blood flow (400). Propranolol decreases variceal 
pressure (367;383;387;401); again, this is also seen in HVPG non responders (383). It might 
be considered that reduction of pressure at the site of bleeding is the closest surrogate pressure 
measurement in relation to bleeding. A decrease in variceal pressure whilst on propranolol 
treatment was found to be associated with a decreased risk of variceal bleeding or rebleeding 
(367). Nitrates decrease variceal pressure when given either orally (368) or sublingually (402) 
or result in no change after intraduodenal infusion despite a marked decrease in arterial 
pressure (403). No data on long-term effects of nitrates on variceal pressure are published. 
This suggests that the effect of propranolol and other non-selective beta blockers on the 
prevention of variceal bleeding may not correlate solely with the degree of portal pressure 
reduction. Some of the therapeutic effects may indeed be due to the changes in collateral 
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blood flow and variceal pressure which also occur in patients who do not achieve a 
haemodynamic response as assessed by a HVPG decrease of 20 % or more (367;383). 
Also, several other factors might be of importance, such as the age of the patients, the dose of 
beta blockers or nitrates used (which varies quite significantly in the different studies), and 
even more so the compliance with the treatment (344;350;351). Recently the importance of 
beta-2 adrenergic receptor gene polymorphism has been investigated(404), but it does not 
seem to predict hemodynamic response to propranolol in patients with cirrhosis (although it 
may allow selecting a subgroup of patients likely to benefit from the addition of 
nitrates)(405). Another possible source of heterogeneity could lie in constitutional factors 
such as the presence of the metabolic syndrome, but little data has been published so far on 
this issue. The importance of technical differences in HVPG measurement and the need for 
standardization have also been pointed out recently (406;407).                    
 
 
2) Non-haemodynamic mechanisms 
 
The role of bacterial infection in variceal bleeding in cirrhotic patients is an ever more 
attractive hypothesis (59;359). Bacterial infections in cirrhotic patients are common (3). There 
is a predisposition to intestinal bacterial overgrowth, intestinal dysmotility and increased 
intestinal permeability, all leading to an increase in bacterial translocation (359). Bacterial 
translocation is the probable mechanism for some of the most common infections in cirrhosis, 
such as spontaneous bacterial peritonitis, but is also the source of bacterial by-products such 
as endotoxin which can cause an increase in portal pressure (culminating in the increased 
portal pressure in the presence of spontaneous bacterial peritonitis(118;408)), an impairment 
of liver function and a worsening of haemostasis (359). 
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The effects of bacterial infection and bacterial products on the portal and systemic 
haemodynamics in cirrhosis and clinical data on infection, from both retrospective and 
prospective studies, of variceal bleeding and other settings, demonstrate the importance of 
infection in pathophysiological mechanisms in cirrhosis (359). This has been followed by 
recent clinical evidence that antibiotic therapy reverses systemic vasodilation (25;108), and 
prevents early variceal rebleeding in two randomised studies (22;299). 
Propranolol has been found to result in faster intestinal transit and lower rates of bacterial 
overgrowth and translocation in cirrhotic rats (36). Interestingly, in a randomised study (albeit 
in abstract form) propranolol reduced the risk of post surgical infections from 42 % to 15 % in 
a cohort of 73 cirrhotic patients (57). Moreover, two recent retrospective studies of 134 and 
139 patients suggested that propranolol may prevent spontaneous bacterial peritonitis 
(58;409), a finding also supported by data from trials for the prevention of variceal bleeding 
(340) or rebleeding (343;410) Indeed, this beneficial effect seems to be obtainable with a 
reduction in portal pressure of as little as 11 %(340), which again points towards the efficacy 
of propranolol even in those who do not have a 20 % reduction of HVPG (309). This effect of 
propranolol is probably due to increasing bowel motility by its sympatholytic action, 
indirectly decreasing microbial translocation  as shown in animal models(36). Given this data 
propranolol may have another mode of action in reducing variceal bleeding by preventing or 
reducing bacterial translocation, or infection, which may trigger bleeding (59;359). 
 
 
The argument against a pure mechanical understanding of variceal haemorrhage 
 
Rupture of oesophageal varices is frequently seen as an event explainable merely by the terms 
of Laplace’s law, as a direct function of variceal pressure and radius and thickness of the 
variceal wall. However, the known risk factors for variceal bleeding (HVPG, liver function, 
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size of varices and presence of red signs) do not readily explain why bleeding and early 
rebleeding occur unpredictably in patients with cirrhosis. Portal pressure rises significantly 
with daily meals as well as exercise (199;200), and oesophageal peristaltic contractions have 
been reported to increase variceal pressure to more than 80 mm Hg (411). Yet despite these 
marked daily changes bleeding episodes are relatively infrequent. 
In the setting of non cirrhotic portal hypertension, where often there are large oesophageal 
varices with red signs, the incidence of bleeding is much lower than in cirrhotics with similar 
varices (196). The bleeding rate in portal vein thrombosis has been documented as 12,5 
episodes per 100 patient years (197;198), whereas the risk of first bleeding with Child grade 
A cirrhotics with large varices and moderate red signs is 24 % in 1 year and in Child grade C 
with small varices and no red signs it is 20 % (195). The difference probably lies in the 
presence of liver disease (although the thrombophilic conditions often associated with portal 
vein thrombosis cannot be discounted). Cirrhosis predisposes to risk of infection, which is not 
reported in non-cirrhotic portal hypertension. In particular bacterial translocation is much less 
frequent in rats with portal vein ligation as compared to cirrhotic rats (64;65). Also, in patients 
with cirrhosis, circulating bacterial DNA fragments (a marker of bacterial translocation) are 
only observed in the presence of ascites suggesting that ascites and advanced liver failure 
contribute to the risk of infection. In the setting of extra-hepatic portal vein obstruction, 
especially in children, haemorrhage may be initiated by a minor, intercurrent infection (412). 
Lastly variceal columns can be composed of several dilated vessels rather than a single vein, 
thus making it more difficult to directly apply Laplace’s law (413). 
Thus a merely mechanical understanding of variceal bleeding as a consequence of portal 
pressure and tension on the variceal wall might not entirely explain the pattern of variceal 
bleeding. Endotoxaemia secondary to bacterial infection may indeed be the critical trigger for 
variceal haemorrhage (59), since it produces a wide series of effects that may predispose the 
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cirrhotic patient to bleeding: impairment of primary and secondary haemostasis, increase of 
portal pressure and worsening of the hyperkinetic syndrome and of liver function (359). 
 
 
Conclusion (Shades of grey) 
 
Portal hypertension causes the development of oesophageal varices and ultimately leads to 
variceal haemorrhage in many patients with cirrhosis. The degree of portal hypertension as 
assessed by HVPG measurement is an independent prognostic factor for survival in cirrhotic 
patients (414). There is little doubt that a low HVPG (<12 mm Hg), either at baseline (415) or 
achieved after a therapeutic intervention such as abstinence from alcohol (416) or 
pharmacological treatment (363-366) is associated with a very low risk of subsequent variceal 
bleeding. An HVPG reduction of 20 % from baseline seems to be of value in terms of 
improving survival and rebleeding(339), even though the effect on the former may be related 
at least in part to changes in liver function(344). 
 
Interestingly different thresholds of portal pressure reduction (≥10 % but < 20 %) have been 
published with regard to protection from complications of portal hypertension other than 
variceal bleeding (309;417), such as SBP (340) and development of oesophageal varices 
(417). In particular Turnes and coworkers (340)showed that an 11 % reduction in HVPG was 
the best cut off in predicting no risk for SBP, thus (since bacterial infection can be the trigger 
for variceal bleeding (359)) protection against haemorrhage might already take place at a 
lower level of HVPG reduction. Furthermore, a haemodynamic response also seems to be 
correlated with an overall better prognosis (343). Thus haemodynamic responders do have a 
better outcome and thus HVPG measurement retains its important prognostic role in 
determining survival (414). A final consideration is that the more commonly used cut-off 
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value (i.e. a 20% reduction in HVPG or to <12 mmHg) was selected to maximize the 
specificity, but is not very sensitive. It could be that the use of a less stringent cut-off (i.e., a 
10% decrease in HVPG) would be more sensitive and markedly reduce the “grey zone”, while 
still being of prognostic value (as an example, the proportion of non-responders using the 
10% cut-off is of about 25%, which is much lower than for the conventional cut-off values) 
(JB, unpublished observations). 
It is thus difficult to consider all haemodynamic non-responders as treatment failures i.e. 
“black”. The effect of propranolol on other haemodynamic parameters such as azygos blood 
flow and on bacterial translocation, together with the fact that more patients do not rebleed 
than achieve the target “protective” HVPG thresholds suggest a more complex picture. While 
some of the haemodynamic non-responders might indeed be “black” and thus doomed to a 
worse prognosis, a substantial part of non-responders are only “grey”: i.e. they do not share 
the appealing pure status of haemodynamic responders, yet are protected from adverse 
outcomes (in particular variceal bleeding) by treatment with non-selective beta blockers 
(Table 22). This is either due to a decrease of collateral and thus variceal blood flow, even 
without a marked decrease in HVPG, and/or due to a reduction of bacterial translocation and 
bacterial infections that may trigger the bleeding itself. Further studies should clarify if 
responses of portal pressure achieved by a proportion of patients (for instance, a decrease of 
10%, 12% or 15%) can uncover part of this “grey” zone. Another way to define this “grey” 
area would be through a randomised controlled trial assigning haemodynamic non-responders 
either to continuation of treatment with non-selective beta blockers, to placebo or to 
endoscopic treatment – but this might well become obsolete in view of the fact that the 
combination of endoscopic banding ligation with non-selective beta blockers seems to be 
superior to endoscopic treatment alone(418;419). Interestingly, a recent study suggested that 
the addition of banding ligation to non-selective beta blockers compared to non-selective beta 
blockade alone was of little added value(420), again suggesting that beta blockers may be 
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acting via other mechanisms to protect against bleeding. Alternatively patients could be 
randomised to long-term antibiotic therapy to test the hypothesis of infection being the trigger 
for variceal bleeding(59;359). Thus, propranolol (or other non-selective beta blockers) may 
well turn out to be the Hepatologist’s “aspirin” – cheap, few contraindications, relatively little 
intolerance and of universal application in cirrhotics irrespective of the presence of varices or 
history of bleeding (344), as they affect outcomes other than bleeding. This therapeutic 
possibility needs urgent exploration, not only because of its potential clinical importance, but 
also because it may define the need for HVPG measurement in the future. 
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FIGURES
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Figure 1: Damage to the intestinal barrier leads to bacterial translocation and endotoxaemia 
and thus to impairment of liver function and increase in portal pressure, possibly causing 
further damage to the gut: a vicious circle 
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Figure 2: Endotoxaemia, bacterial translocation and bacterial infection may be different 
expressions of the same process at different degress of severity, and are associated with 
increasingly severe complications 
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Figure 3: Possible pathophyisiological pathways through which bacterial infection can trigger 
variceal haemorrhage 
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Figure 4: TEG variables. The R time is the time between activation of the sample with 
calcium, and the point where the amplitude of the tracing reaches 2mm, representing the 
formation of the first fibrin strands. The K time is measured from this point until the 
amplitude reaches 20mm, representing the time taken for a fixed degree of viscoelasticity to 
develop, as a result of fibrin build-up and crosslinking. The α-angle is that formed by the 
slope of the TEG tracing between the R time and the K time, and denotes the speed at which 
solid clot forms. The maximum amplitude is the greatest amplitude on the TEG trace and is a 
reflection of the absolute strength of the fibrin clot. The TEG parameters can be affected by 
qualitative and quantitative differences in platelets and the proteins of the clotting cascade, 
and hyperfibrinolytic states. 
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Figure 5:  Bland-Altman plots of the degree of agreement for each TEG parameter in both 
patients (n=50) and healthy volunteers (n=21) between non-kaolin activated native blood and 
non-kaolin activated citrated blood. Dotted lines indicate 1.96 standard deviations from the 
mean. 
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Figure 6: Panel A) Diagramatic thromboelastographic trace showing standard TEG 
parameters. Panel B) Thromboelastographic trace showing a typical heparinase effect as 
found in patient 2, 42 hours after the first haematemesis (Black line standard TEG, Grey line 
heparinase I-modified TEG) 
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Figure 7: Comparison of standard and heparinase I-modified thromboelastography with 
respect to r time in two patients with variceal bleeding. 
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Figure 8: PCR detection of bacterial DNA in ascitic fluid and serum samples from patient 3.  
From left to right: Lane 1, positive control (E.coli DNA); Lane 2, ascitic fluid;  Lanes 3-5 
serum from days 1, 2 and 3; Lane 6, negative control (water instead of DNA); Lane 8, 
positive control (E.coli DNA); Lane 9: ascitic fluid; Lane 10, serum from day 1; Lane 11, 
negative control (water).  
Lanes 1 to 6, PCR performed with BR1 universal primers; Lanes 8 to 11, PCR performed 
with EntB primers. Lanes 7 and 12: molecular weight markers.  
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Figure 9:  Data of measurements in all patients. A) Correlation between WHVP and PVP 
(n=320); B) corresponding agreement between WHVP and PVP according to Altman and 
Bland; C) correlation between HVPG and PPG (n=75); D) corresponding agreement between 
HVPG and PPG according to Altman and Bland. Dotted lines: 1.96 standard deviations.
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Figure 10: Data of measurements in patients with alcoholic liver disease. A) Correlation 
between WHVP and PVP (n=102); B) corresponding agreement between WHVP and PVP 
according to Altman and Bland; C) correlation between HVPG and PPG (n=13); D) 
corresponding agreement between HVPG and PPG according to Altman and Bland. Dotted 
lines: 1.96 standard deviations. 
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Figure 11: A) Correlation between WHVP and PVP in patients with non-alcoholic liver 
disease (n=88); B) corresponding agreement between WHVP and PVP according to Altman 
and Bland in patients with non-alcoholic liver disease; C) correlation between WHVP and 
PVP in patients with HCV related liver disease (n=53); D) corresponding agreement between 
WHVP and PVP according to Altman and Bland in patients with HCV related liver disease. 
Dotted lines: 1.96 standard deviations. 
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Figure 12: A) Correlation between WHVP and PVP measurements performed with a wedge 
catheter (n=194); B) corresponding agreement between WHVP and PVP according to Altman 
and Bland measurements performed with a wedge catheter; C) correlation between WHVP 
and PVP measurements performed with a balloon catheter (n=113); D) corresponding 
agreement between WHVP and PVP according to Altman and Bland measurements 
performed with a balloon catheter. Dotted lines: 1.96 standard deviations. 
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Figure 13: Assessment of the difference between the two types of measurement plotted 
against portal vein pressure for measurements in all patients (absolute difference, A and 
percentage change from WHVP, B) and measurements with balloon catheter (absolute 
difference, C and percentage change from WHVP, D). 
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Reaction (R) time  (9.4 - 27.4 minutes) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
14.2 
13.8 
12.7 
15.0 
13.6 
14.2 
± 1.3 
± 1.0 
± 0.8 
± 1.6 
± 1.5 
± 1.5 
17.0 
19.0 
26.4 
46.0 
55.6 
60.0 
± 1.4 
± 1.9 
± 1.8 
± 5.0 
± 4.4 
± 0.0 
17.8 
17.2 
15.9 
26.5 
50.6 
59.3 
± 1.1 
± 1.7 
± 1.2 
± 3.4 
± 5.5 
± 0.7 
16.7 
20.1 
19.6 
27.0 
43.3 
56.7 
± 2.0 
± 4.1 
± 2.1 
± 3.7 
± 4.4 
± 3.3 
K time  (1.9-8.9 minutes) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
5.5 
5.2 
5.0 
5.2 
5.2 
4.5 
± 0.4 
± 0.5 
± 0.5 
± 0.4 
± 0.5 
± 0.6 
7.1 
8.8 
15.2 
41.7 
55.0 
60.0 
± 0.8 
± 1.0 
± 1.6 
± 7.5 
± 5.0 
± 0.0 
9.8 
9.1 
9.3 
19.1 
50.2 
60.0 
± 1.3 
± 1.8 
± 1.3 
± 5.0 
± 6.6 
± 0.0 
8.3 
8.9 
9.6 
17.2 
34.7 
56.4 
± 1.5 
± 1.2 
± 1.9 
± 2.6 
± 6.5 
± 3.6 
α-angle  (22-58 degrees) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
39.9 
40.1 
41.2 
39.1 
39.6 
45.5 
± 3.1 
± 2.2 
± 3.3 
± 2.9 
± 2.5 
± 2.8 
28.9 
26.0 
16.6 
8.0 
2.0 
0.0 
± 3.1 
± 3.1 
± 2.1 
± 3.5 
± 2.0 
± 0.0 
24.1 
25.7 
30.0 
17.7 
6.0 
0.0 
± 2.6 
± 2.4 
± 2.4 
± 2.2 
± 3.7 
± 0.0 
29.3 
29.2 
27.5 
19.8 
9.8 
1.1 
± 4.7 
± 3.7 
± 4.1 
± 3.2 
± 3.1 
± 1.1 
Maximum amplitude (MA) (44.4-63.6 mm) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
48.3 
46.3 
50.1 
48.6 
47.8 
53.2 
± 1.6 
± 1.6 
± 1.4 
± 1.2 
± 0.9 
± 1.2 
43.6 
41.2 
40.3 
15.5 
3.7 
0.0 
± 1.3 
± 1.6 
± 1.8 
± 5.3 
± 3.7 
± 0.0 
41.8 
42.8 
42.7 
35.1 
9.2 
1.4 
± 1.6 
± 2.1 
± 1.4 
± 4.5 
± 5.8 
± 1.4 
43.9 
38.2 
43.1 
39.1 
24.0 
5.4 
± 2.5 
± 3.7 
± 1.8 
± 2.3 
± 6.7 
± 5.4 
Table 1A 
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Prothrombin time (PT) (12 - 16 s) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
14.0 
13.8 
14.0 
14.3 
14.3 
14.7 
± 0.2 
± 0.2 
± 0.2 
± 0.3 
± 0.3 
± 0.3 
14.2 
14.2 
14.8 
15.9 
18.0 
26.9 
± 0.3 
± 0.2 
± 0.2 
± 0.7 
± 0.7 
± 2.4 
14.0 
14.2 
14.8 
15.8 
16.6 
19.0 
± 0.3 
± 0.3 
± 0.6 
± 0.7 
± 0.4 
± 0.4 
14.22 
14.34 
14.44 
14.79 
16.04 
17.51 
± 0.3 
± 0.3 
± 0.3 
± 0.2 
± 0.3 
± 0.3 
Activated partial thromboplastin time (aPTT) (28 - 38 s) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
32.4 
32.3 
32.6 
33.1 
33.6 
34.8 
± 0.8 
± 0.7 
± 1.0 
± 0.7 
± 0.6 
± 0.8 
33.2 
34.3 
41.1 
78.3 
130.4 
146.1 
± 1.2 
± 1.5 
± 3.2 
± 13.4 
± 12.7 
± 14.2 
32.4 
33.4 
39.5 
43.9 
66.5 
125.0 
± 2.0 
± 2.2 
± 3.6 
± 2.1 
± 5.9 
± 10.0 
33.5 
35.8 
37.5 
46.1 
59.2 
90.1 
± 1.1 
± 1.2 
± 1.2 
± 1.7 
± 2.6 
± 5.6 
Thrombin time (TT) (13 - 17 s) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
14.7 
15.3 
15.1 
15.4 
15.2 
15.7 
± 0.4 
± 0.5 
± 0.3 
± 0.6 
± 0.4 
± 0.4 
15.6 
16.7 
49.2 
55.4 
60.0 
60.0 
± 0.5 
± 1.2 
± 5.6 
± 4.6 
± 0.0 
± 0.0 
16.3 
15.1 
23.6 
60.0 
60.0 
60.0 
± 1.3 
± 0.4 
± 4.3 
± 0.0 
± 0.0 
± 0.0 
14.7 
15.1 
15.0 
27.6 
30.5 
50.1 
± 0.4 
± 0.4 
± 0.3 
± 5.6 
± 5.1 
± 5.1 
Anti-Xa activity (U/ml) 
U / ml Saline UFH LMWH DPD 
0.025 
0.050 
0.100 
0.250 
0.500 
1.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
± 0.000 
± 0.000 
± 0.000 
± 0.000 
± 0.000 
± 0.000 
0.019 
0.049 
0.133 
0.321 
0.703 
0.894 
± 0.007 
± 0.012 
± 0.024 
± 0.033 
± 0.043 
± 0.043 
0.026 
0.053 
0.099 
0.211 
0.599 
0.924 
± 0.006 
± 0.007 
± 0.008 
± 0.021 
± 0.043 
± 0.060 
0.031 
0.081 
0.101 
0.302 
0.611 
0.925 
± 0.010 
± 0.031 
± 0.013 
± 0.033 
± 0.036 
± 0.049 
Table 1B 
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Tables 1A and 1B: Comparison of TEG parameters (table 1a) with conventional coagulation 
tests (table 1b) for detecting the presence of heparins and Danaparoid in blood. The mean 
results ± SEM from 10 subjects with each drug are presented. Saline control values shown are 
the mean of 9 samples (3 subjects, 3 drugs) ± SEM. The reference range for each parameter is 
shown in brackets. Values outwith the reference range are underlined. UFH = unfractionated 
heparin; LMWH = low molecular weight heparin (Fragmin); DPD = Danaparoid (Orgaran). 
Straight-line traces were arbitrarily assigned R and K values of 60 mins, α-angles of 0° and 
MAs of 0mm 
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Reaction R time  (9.4 - 27.4 minutes) 
U / ml UFH +Hep’ase P< LMWH +Hep’ase P< DPD +Hep’ase P< 
0.005 
0.010 
0.025 
0.050 
16.4 
16.5 
18.5 
21.7 
±1.6 
±1.3 
±1.2 
±1.8 
14.4 
15.3 
13.7 
14.4 
±0.9 
±1.3 
±1.1 
±1.6 
.2 
.2 
.001 
.001 
16.0 
17.8 
18.7 
18.7 
±0.9 
±1.6 
±1.1 
±2.0 
12.6 
13.1 
12.9 
13.1 
±1.1 
±0.8 
±0.9 
±0.6 
.001 
.01 
.001 
.02 
15.4 
16.8 
17.2 
21.8 
±1.4 
±1.5 
±1.9 
±3.9 
12.3 
13.6 
12.4 
13.2 
±1.3 
±1.1 
±1.2 
±1.1 
.01 
.05 
.01 
.05 
K time  (1.9-8.9 minutes) 
U / ml UFH +Hep’ase P< LMWH +Hep’ase P< DPD +Hep’ase P< 
0.005 
0.010 
0.025 
0.050 
7.1 
6.7 
8.8 
12.2 
±0.9 
±0.5 
±0.8 
±1.4 
5.1 
5.4 
4.5 
4.6 
±0.6 
±0.5 
±0.6 
±0.6 
.05 
.01 
.01 
.001 
9.2 
10.0 
11.2 
11.5 
±1.1 
±1.4 
±1.1 
±2.1 
4.1 
4.4 
4.1 
4.4 
±0.6 
±0.5 
±0.5 
±0.4 
.01 
.01 
.001 
.01 
8.2 
9.5 
9.0 
10.6 
±1.2 
±1.5 
±1.3 
±1.0 
3.7 
4.2 
4.0 
4.4 
±0.5 
±0.4 
±0.7 
±0.7 
.01 
.01 
.01 
.001 
α-angle  (22-58 degrees)  
U / ml UFH +Hep’ase P< LMWH +Hep’ase P< DPD +Hep’ase P< 
0.005 
0.010 
0.025 
0.050 
29.4 
29.9 
23.7 
18.6 
±2.5 
±2.1 
±1.9 
±1.8 
38.3 
37.1 
40.9 
41.6 
±2.9 
±2.5 
±3.9 
±3.5 
.01 
.001 
.01 
.001 
24.0 
22.2 
20.0 
21.8 
±2.2 
±2.4 
±1.9 
±2.9 
45.6 
44.4 
46.4 
42.2 
±4.6 
±3.4 
±3.4 
±2.6 
.01 
.01 
.001 
.001 
27.2 
24.3 
25.8 
24.2 
±3.1 
±2.9 
±4.1 
±3.4 
48.3 
44.3 
46.3 
43.8 
±3.8 
±2.8 
±4.4 
±4.2 
.01 
.001 
.01 
.01 
Maximum amplitude (MA; 44.4-63.6 mm) 
U / ml UFH +Hep’ase P< LMWH +Hep’ase P< DPD +Hep’ase P< 
0.005 
0.010 
0.025 
0.050 
44.8 
45.8 
43.1 
41.0 
±2.0 
±1.2 
±1.4 
±1.4 
47.7 
50.1 
51.8 
50.7 
±2.3 
±2.3 
±2.6 
±3.1 
.2 
.001 
.01 
.01 
40.0 
40.6 
40.0 
39.5 
±1.9 
±2.5 
±1.2 
±2.0 
51.1 
51.5 
53.5 
51.3 
±2.9 
±2.3 
±2.8 
±2.2 
.01 
.02 
.001 
.01 
42.6 
42.6 
42.5 
36.5 
±2.0 
±1.7 
±2.4 
±3.6 
51.5 
51.5 
50.9 
51.1 
±2.8 
±1.8 
±2.5 
±3.0 
.01 
.01 
.01 
.01 
 Prothrombin time (PT) (12 - 16s) 
 
aPTT (28 - 38s) 
U / ml UFH LMWH Danaparoid UFH LMWH Danaparoid 
0.005 
0.010 
0.025 
0.050 
14.4 
14.2 
14.3 
14.4 
± 0.3 
± 0.3 
± 0.3 
± 0.3 
14.3 
14.4 
14.3 
14.5 
± 0.3 
± 0.4 
± 0.3 
± 0.3 
14.4 
14.4 
14.4 
14.6 
± 0.4 
± 0.3 
± 0.3 
± 0.4 
33.8 
33.6 
34.4 
35.4 
± 1.4 
± 1.3 
± 1.4 
± 1.6 
34.3 
34.2 
34.4 
35.8 
± 1.4 
± 1.3 
± 1.4 
± 1.6 
33.5 
33.3 
35.0 
37.4 
± 1.1 
± 1.1 
± 1.2 
± 1.3 
 Thrombin time (TT) (13 - 17s) Anti-Xa activity (U/ml) 
U / ml UFH LMWH Danaparoid UFH LMWH Danaparoid 
0.005 
0.010 
0.025 
0.050 
15.1 
14.1 
15.6 
17.0 
± 0.5 
± 0.2 
± 0.5 
± 1.1 
14.5 
14.2 
16.3 
15.4 
± 0.2 
± 0.3 
± 1.2 
± 0.4 
15.5 
14.3 
14.9 
15.5 
± 0.7 
± 0.3 
± 0.4 
± 0.4 
0.034 
0.034 
0.044 
0.052 
± .013 
± .014 
± .029 
± .022 
0.007 
0.013 
0.018 
0.038 
± .004 
± .005 
± .006 
± .010 
0.004 
0.009 
0.029 
0.083 
± .002 
± .003 
± .010 
± .031 
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Table 2: Comparison of standard and heparinase modified TEG parameters with conventional 
coagulation tests for detecting the presence of low concentrations of heparins and Danaparoid 
in blood. The mean results ± SEM from 10 subjects with each drug are presented. Paired t-test 
p-values demonstrate statistically significant differences between TEG parameters with and 
without heparinase modification at all but the lowest concentrations of UFH used in this study 
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Summary 
Slopes 
 UFH  LMWH  Danaparoid 
 
 
Mean ±SEM P <  Mean ±SEM P <  Mean ±SEM P < 
R time  44.4 1.3 0.0001  48.0 1.1 0.0001  41.8 3.3 0.0001 
K time  56.2 1.3 0.0001  57.9 1.4 0.0001  51.1 4.0 0.0001 
α angle  -27.4 2.5 0.0001  -29.5 1.6 0.0001  -30.4 3.2 0.0001 
MA  -47.2 1.6 0.0001  -47.1 2.6 0.0001  -39.0 6.5 0.0001 
 
Table 3A: Mean (n=10) of summary slopes representing the change in each TEG parameter 
vs. anticoagulant concentration (0.025 to 1.0 U/ml) 
 
 
 
Summary 
Slopes 
 UFH  LMWH  Danaparoid 
 
 
Mean ±SEM P <  Mean ±SEM P <  Mean ±SEM P < 
R time  121.7 37.5 0.02  47.9 29.7 0.2  133.4 86.9 0.2 
K time  123.4 38.3 0.02  47.4 30.6 0.2  40.7 35.6 0.3 
α angle  -259.0 72.9 0.01  -40.3 55.5 0.5  -40.5 112.2 0.8 
MA  -119.32 40.9 0.02  -11.9 36.9 0.8  -136.2 83.2 0.2 
 
Table 3B: Mean (n=10) of summary slopes representing the change in each TEG parameter 
vs. anticoagulant concentration (0.005 to 0.5 U/ml) 
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Slope Pairs 
(Standard vs 
heaprinase) 
 UFH  LMWH  Danaparoid 
 
 
Mean ± SEM P <  Mean ± SEM P <  Mean 
± 
SEM P 
R time  133.5 37.5 0.01  42.0 28.3 0.2  126.5 81.9 0.2 
K time  137.8 40.3 0.01  44.0 31.2 0.2  29.6 43.1 NS (0.51) 
α angle  -352.0 104.0 0.01  22.9 80.5 NS (0.78)  23.6 182.9 
NS 
(0.9) 
MA  -179.8 65.1 0.05  -13.3 56.4 NS (0.82)  -126.5 100.4 
NS 
(0.24) 
             
Anti-Xa  0.3 0.4 NS (0.43)  0.7 0.2 0.02  1.8 0.7 0.05 
 
Table 4: Mean difference (n=10) between standard and heparinase modified TEG summary 
slopes representing the change in each parameter vs. anticoagulant concentration (0.005 to 0.5 
U/ml), compared with mean (n=10) of summary slopes representing the change in anti-Xa 
activity vs. anticoagulant concentration (0.005 to 0.5 U/ml) 
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 Age (±S.D.) Male/Female Child score(±S.D.) INR (±S.D.) Enoxaparin 20/40 mg 
Group 1 31.8±4.7 13/8    
Group 2 52.3±8.2 10/10 9±1.8   
Group 3 49.4±11.4 4/6    
Group 4 55.2±17.5 6/4  3.0±1.0  
Group 5 55.8±15.9 8/2   4/6 
 
 
Table 5: Demographics of healthy volounteers (Group1) and patients (Group 2-5) 
 
 
 
 
 
 
 
 
 
 r time k time α angle MA 
Total 0.70 0.46 0.52 0.69 
Group 1 0.18 0.53 0.58 0.69 
Group 2 0.68 0.67 0.67 0.77 
Group 3 0.60 - 0.56 - 0.68 0.22 
Group 4 0.77 0.31 0.57 - 0.02 
Group 5 0.90 0.71 0.78 0.75 
 
 
Group 1 – 21 healthy volunteers 
Group 2 – 20 patients with non-biliary cirrhosis 
Group 3 – 10 patients with PBC/PSC 
Group 4 – 10 patients on warfarin 
Group 5 – 10 patients on enoxaparin prophylaxis 
 
Table 6: Correlation (Spearman r) between native blood and kaolin-activated native blood 
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 r time k time α angle MA 
Total 0.37 0.07 0.19 0.80 
Group 1 0.46 0.44 0.56 0.68 
Group 2 0.19 0.14 0.31 0.80 
Group 3 0.47 - 0.13 - 0.07 0.7 
Group 4 0.53 - 0.28 - 0.20 0.49 
Group 5 0.73 0.33 0.32 0.49 
 
 
Group 1 – 21 healthy volunteers 
Group 2 – 20 patients with non-biliary cirrhosis 
Group 3 – 10 patients with PBC/PSC 
Group 4 – 10 patients on warfarin 
Group 5 – 10 patients on enoxaparin prophylaxis 
 
Table 7: Correlation (Spearman r) between citrated blood and kaolin-activated citrated blood  
 
 
 
 
 r time k time α angle MA 
Total 0.46 0.46 0.47 0.71 
Group 1 0.47 0.56 0.62 0.71 
Group 2 0.35 0.34 0.36 0.71 
Group 3 0.17 0.08 - 0.31 0.19 
Group 4 0.36 0.66 0.82 0.19 
Group 5 0.84 0.90 0.82 0.75 
 
 
Group 1 – 21 healthy volunteers 
Group 2 – 20 patients with non-biliary cirrhosis 
Group 3 – 10 patients with PBC/PSC 
Group 4 – 10 patients on warfarin 
Group 5 – 10 patients on enoxaparin prophylaxis 
 
Table 8: Correlation (Spearman r) between native blood and citrated blood (non kaolin-
activated) 
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 Total Group1 Group 2 Group 3 Group 4 Group 5 
r-time native vs citrated 0.7980 0.0021* 0.2820 0.3750 0.0098* 0.0645 
k-time native vs citrated 0.2145 0.0002* 0.7724 0.9219 0.0195* 0.1934 
α angle native vs citrated 0.2042 0.0001* 0.9777 1.0000 0.1055 0.3750 
ma native vs citrated <0.0001* 0.0004* 0.0067* 0.6250 0.0645 0.0840 
 
* p<0.05 
 
Group 1 – 21 healthy volunteers 
Group 2 – 20 patients with non-biliary cirrhosis 
Group 3 – 10 patients with PBC/PSC 
Group 4 – 10 patients on warfarin 
Group 5 – 10 patients on enoxaparin prophylaxis 
 
Table 9: Wilcoxon’s matched pair test p values for native and citrated blood samples (kaolin 
activated and non-kaolin activated) 
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  Group1 Group2 Group3 Group4 Group5 
Kruskal-Wallis 
p 
Native r time 23.314±5.243      20.290±7.169       17.170±4.480      23.890±8.619      27.770±19.988 0.0437 
Native k time 9.238±2.830* 7.620±4.939       5.490±2.015*      9.080±4.642       9.460±6.754 0.0320 
Native α angle 24.305±6.533*     32.670±13.598      40.160±10.488*     29.800±16.234      33.080±14.292 0.0166 
Native MA 48.524±6.082*$      48.570±8.716&%      63.350±8.027*&     57.280±9.732      65.940±11.300$% 0.0000 
  
            
Citrated r time 19.290±3.933§      22.670±6.867      21.340±10.282#     37.380±12.211§#!     23.590±17.842! 0.0038 
Citrated k time 6.095±2.108§      7.415±3.586       5.540±2.641#      18.980±13.849§#      8.340±7.021 0.0211 
Citrated α angle 34.648±10.646      31.155±9.950      39.010±14.289#     20.600±12.000#     36.130±16.911 0.0281 
Citrated MA 55.414±8.625$      53.215±9.862&"%      65.410±8.686&      65.000±8.043"%      69.840±9.807$ 0.0001 
 
      
Native r time (Kaolin) 5.914±1.182*       4.890±1.130       4.400±0.924*      5.630±2.213       4.650±1.439 0.0109 
Native k time (Kaolin) 1.448±0.218*$     1.905±1.528&%       1.060±0.222*&      1.340±0.420       1.060±0.222$% 0.0004 
Native α angle (Kaolin) 69.157±3.145*$     66.290±10.448&%      74.760±2.950*&      71.300±5.283       75.980±2.693$% 0.0000 
Native MA (Kaolin) 64.762±4.393$      55.415±9.465&"%      69.350±5.817&     66.930±10.243"      74.330±4.996$% 0.0000 
 
* Significant difference between groups 1-3 
$ Significant difference between groups 1-5 
& Significant difference between groups 2-3 
% Significant difference between groups 2-5 
§ Significant difference between groups 1-4 
# Significant difference between groups 3-4 
! Significant difference between groups 4-5 
"Significant difference between groups 2-4 
 
 
Table 10: Differences between group 
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Age (mean±2*S.D.) 48.8±28.6 
Gender (M/F) 6/4 
Aetiology  
      Alcohol 6 
      Budd Chiari 2 
      Hepatitis C Virus 1 
      Cryptogenic 1 
Indication for TIPS  
      Recurrent bleeding 4 
      Refractory ascites/hydrothorax 3/1 
      Budd Chiari 2 
Child class (A/B/C) 1/5/4 
Child score (mean±2*S.D.) 8.8±3.6 
 
 
Table 11: Demographics of the patients recruited for the study.  
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Patient Aetiology Indication Child score TEG variable Baseline Day 0 Day 1 Day 2 
Patient 1 Hepatitis C Hydrothorax 8      
    r time - - -  
    k time - - -  
    alpha angle - - -  
    ma - - -  
Patient 2 Cryptogenetic Ascites 9      
    r time - - + - 
    k time - + + - 
    alpha angle - - + - 
    ma - - - - 
Patient 3 Alcohol Bleeding 7      
    r time - - -  
    k time - - +  
    alpha angle - - -  
    ma - - -  
Patient 4 Alcohol Bleeding 10      
    r time - - - - 
    k time + - - - 
    alpha angle + - - - 
    ma - - - - 
Patient 5 Alcohol Ascites 10      
    r time - + + - 
    k time - + - - 
    alpha angle - + - - 
    ma - - - - 
Patient 6 Alcohol Bleeding 7      
    r time - + - - 
    k time - + - - 
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    alpha angle - + - - 
    ma - - - - 
Patient 7 Alcohol Bleeding 9      
    r time - + -  
    k time - - -  
    alpha angle - + -  
    ma - - -  
Patient 8 Alcohol Ascites 7      
    r time + - - - 
    k time - + - - 
    alpha angle - + - - 
    ma - - - - 
Patient 9 Budd Chiari Budd Chiari 6      
    r time - + -  
    k time - + -  
    alpha angle - + -  
    ma - - -  
Patient 10 Budd Chiari Budd Chiari 10      
    r time - + -  
    k time - + -  
    alpha angle - + -  
    ma - - -  
 
 
 
Table 12: Summary of findings 
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Primer Sequence Amplified gene Gene product Amplicon size  
(in bp) 
Detected bacteria 
BR1 GGACTACCAGGGTATCTAAT 
AGAGTTTGATCCTGGCT 
(See Ref. 9) 
16S rDNA gene Ribosomic DNA 16S 804 All 
EntB TGAATCACAAAGTGGTAAGCG 
TGGGGATGACGTCAAGTCAT 
 
hly Haemolysin 300 Enterobacteriaceae 
Eco ATCATGGAAGTAAGACTGC 
TTGCTGTGCCAGGCAGTTT 
 
uidA β glucuronidase 356 E. coli 
pbp5 CATGAGCAATTAATCGG 
CATAGCCTGTCGCAAAAC 
pbp5 Penicillin binding protein 5 444 E. faecalis 
 
 
Table 13: Characteristics of the primers used in this study 
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Age (mean±2*S.D.) 57.7±25.1 
Sex (M/F) 6/1 
Aetiology  
       Alcohol 3 
       HCV 2 
       HBV 1 
       HCV+Alcohol 1 
Ascites (present/absent) 4/3 
Child class (A/B/C) 4/3/0 
Child score (mean±2*S.D.) 6.7±3.8 
Diuretics (yes/no) 4/3 
Varices (yes/no) 6/1 
 
 
Table 14: Demographics of the patients studied 
 
 
 
Albumin (mean±2*S.D.) 34.3±14.6 g/L 
Bilirubin (mean±2*S.D.) 1.9±2.8 mg/dL 
INR (mean±2*S.D.) 1.2±0.3 
Haemoglobin (mean±2*S.D.) 13.6±3.4 g/dL 
White cell count (mean±2*S.D.) 6050±3958 per mm3 
Platelets (mean±2*S.D.) 124000±43000 per mm3 
Creatinine (mean±2*S.D.) 0.86±0.37 mg/dL 
Sodium (mean±2*S.D.) 139±4 mmol/L 
AST (mean±2*S.D.) 122±115 IU/L 
ALT (mean±2*S.D.) 101±171 IU/L 
Urinary sodium (mean±2*S.D.) 92±72 mmol/24 hours 
Mean arterial blood pressure (mean±2*S.D.) 92±10 mm Hg 
 
Table 15: Baseline values. INR: International normalised ratio, AST: Aspartate 
aminotransferase, ALT: Alanine aminotransferase 
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Patient Aetiology Ascites DNA in  serum or ascites Transit time Permeability Bacterial overgrowth 
1 HCV Yes No Decreased Increased No 
2 HCV + Alcohol No No Normal Increased No 
3 HCV Yes Yes Decreased Increased No 
4 Alcohol Yes No Decreased Increased No 
5 HBV No No Decreased Increased Yes 
6 Alcohol No No Decreased Increased No 
7 Alcohol Yes No Decreased Increased No 
 
 
 
 
 
Table 16: Summary of findings 
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Patient Urine volume 
(mL) 
Urinary mannitol 
(mmol/L) 
Urinary lactulose 
(mmol/L) 
%M %L %L/%M 
1 590 4.9 0.25 10.5 0.5 0.047 
2 530 4.8 0.31 9.42 0.56 0.059 
3 150 11.1 0.866 6.1 0.44 0.072 
4 230 21.01 1.2 17.7 0.94 0.053 
5 320 6.5 0.24 7.6 0.26 0.036 
6 140 16.1 0.72 8.2 0.35 0.042 
7 200 12.1 0.36 8.8 0.24 0.027 
 
 
 
 
Table 17: Excretion of mannitol and lactulose in patients with cirrhosis. %M: percentage of mannitol excreted; %L: percentage of lactulose 
excreted; %L/%M: excrection ratio. 
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Author Year  Patients 
n 
Aetiology ALD  
% 
Cirrhosis 
% 
Method of 
WHVP 
Method of PVP 
Reynolds (16) 1955 19 ALD 100 100 wedge Direct portal vein catheterization 
Joly (22) 1968 19 n/a n/a 100 wedge Umbilical vein catheterization 
Reynolds (11) 1970 22 ALD, Non ALD 73 <73 wedge Umbilical vein catherization 
Viallet (6) 1970 43 ALD, Non ALD 93 100 wedge Umbilical vein catherization 
Boyer (7) 1977 78 ALD, Non ALD 58 n/a wedge Percutaneous transhepatic puncture 
Okuda (15) 1977 13 n/a n/a 100 n/a Percutaneous transhepatic puncture 
Valla (12) 1984 7 ALD 100 100 wedge Percutaneous transhepatic puncture 
Rector (10) 1985 6 ALD 100 100 wedge Percutaneous transhepatic puncture 
Lin (13) 1989 21 HBV 0 100 balloon Percutaneous transhepatic puncture 
Deplano (14) 1999 21 HCV 0 100 balloon Percutaneous transhepatic puncture 
Perello (8) 1999 71 ALD, HCV 55 89 balloon Percutaneous transhepatic and 
transjugular puncture 
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ALD – Alcoholic liver disease; Non ALD – causes other than alcoholic liver disease; HBV – 
hepatitis B virus related liver disease; HCV – hepatitis C virus related liver disease; n/a – not 
available 
 
Table 18: Studies comparing portal and wedge pressures included in the systemical 
evaluation 
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Total n of patients with known 
haemodynamic response 
167 (211) 
Haemodynamic responders 73 (101) 
      % Rebleeding 10.9% (19.8%) 
Haemodynamic non responders 94 (110) 
      % Rebleeding 52.1% (48.2%) 
Patients rebleeding 57 (73) 
      % Non responders 85.9% (72.6%) 
Patients not rebleeding 110 (138) 
      % Non responders 40.9% (41.3%) 
 
 
Table 19: Breakdown according to haemodynamic response and rebleeding of patients with 
known haemodynamic response in 5 trials for prevention of variceal rebleeding (360-364). In 
parentheses the same data including the outlier study (361) 
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Patients with known haemodynamic response
Total 167 (211)
Responders 73 (101) Non responders 94 (110)
No Rebleeding
65 (81)
Rebleeding
8 (20)
Rebleeding
49 (53)
No rebleeding
45 (57)
TN FN TP FP
Positive predictive value (PPV): 52.1 % (48.1 %)
Negative predictive value (NPV): 89 % (80.2 %)
 
 
 
 
 
 
Table 20: Positive predictive value (PPV) and negative predictive value (NPV) of 
haemodynamic non-response for variceal rebleeding. In parentheses the same data including 
the outlier study (361). TN: True negatives, FN: False negatives, FP: False positives, TP: True 
positives 
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Effects of non-selective beta blockers
Reduction of HVPG by
≥20% or to ≤12 mm Hg
Reduction of HVPG by
<20%
Reduction of azygos blood
flow/collateral blood flow
Reduction of variceal
pressure
Reduction of bacterial
translocation
Mechanism Comment
By definition only in responders
Possible in non responders
Both in responders and non responders
Both in responders and non 
responders, but greater in responders
Both in responders and non responders
 
 
 
Table 21: Different protective effects of non-selective beta blockers in haemodynamic 
responders and non responders 
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BLACK, WHITE & GREY 
 
 
 
BLACK: Haemodynamic non responders who bleed or rebleed from varices (? and 
haemodynamic responders who bleed or rebleed from varices) 
 
WHITE: Haemodynamic responders who do not bleed or rebleed 
 
GREY: Haemodynamic non responders who do not bleed or rebleed 
 
 
 
Table 22: Three different patient populations as identified by response to non-selective beta 
blockers and risk of variceal haemorrhage 
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